[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"psoriasis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:psoriasis":27},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,112,0,25,[9,41,62,83,105,129,158,185,203,226,258,281,303,328,351,379,404,425,464,489,512,535,557,586,607],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100648397","phase-2-phase-ii-clinical-trial-of-shr-1139-injection-in-patients-with-psoriasis-100648397",false,"NCT07719530","Phase II Clinical Trial of SHR-1139 Injection in Patients With Psoriasis","A Multicenter, Randomized, Double-blind, Parallel-group Phase II Clinical Study to Evaluate the Efficacy and Safety of SHR-1139 Injection in Patients With Moderate to Severe Plaque Psoriasis","Inclusion Criteria:\n\n1. During the screening process, the body mass index (BMI = weight (kg) \u002F height\\^2 (m\\^2)) was ≥ 18 kg\u002Fm\\^2;\n2. History of plaque psoriasis for more than 6 months before randomization；\n3. The PASI score, sPGA score, and BSA at the screening and baseline required certain requirements;\n4. Participants suitable for phototherapy or systemic psoriasis treatment for moderate to severe plaque psoriasis;\n5. Participants voluntarily signed the informed consent before any procedures related to the study, could communicate smoothly with the researchers, understood and were willing to strictly follow the requirements of this clinical study protocol to complete the study;\n6. Female participants with reproductive capacity or their male partners with reproductive capacity, starting from the date of signing the informed consent until 72 weeks after the last medication, had no plans for pregnancy, sperm donation, or egg donation, and voluntarily took effective contraceptive measures. The pregnancy test results of female participants during the screening period and before random administration should be negative, and must be non-lactating.\n\nExclusion Criteria:\n\n\\-\n\nThe following conditions or diseases must be absent:\n\n1. The diagnosed psoriasis at the screening or baseline stage is not chronic plaque-type psoriasis;\n2. Has drug-induced psoriasis;\n3. Has other skin problems that the investigator considers would interfere with the assessment of psoriasis;\n4. Has concurrent other active autoimmune diseases, including but not limited to rheumatoid arthritis, systemic lupus erythematosus, scleroderma, polymyositis, multiple sclerosis or other central demyelinating diseases, primary Sjögren's syndrome, etc.;\n\nUsing the following drugs or participating in clinical studies:\n\n1. During the pre-baseline period, other biological agents had been used but did not meet the washout requirements.\n2. Has used drugs targeting the same target before the screening;\n3. Has received systemic psoriasis treatment drugs within the specified period before the baseline;\n4. Has received topical psoriasis treatment drugs within the specified period before the baseline;\n5. Has received phototherapy within the specified period before the baseline;\n6. Has participated in any clinical study of drugs or medical devices within 3 months before the baseline or within the drug's half-life period;\n\nImportant conditions or underlying diseases that affect safety:\n\n1. The participant has a history of lymphocytic proliferative diseases;\n2. The participant has had any active malignant tumor or history of malignant tumor within the previous 5 years before the screening;\n3. Has a history of moderate to severe congestive heart failure (NYHA cardiac function classification ≥ III) within 3 months before the screening, has experienced cardiovascular or cerebrovascular events or severe bleeding events, and the investigator considers this participant unsuitable for participating in the clinical study;\n4. Has had opportunistic infections or immunodeficiency diseases within the previous 6 months before the screening;\n5. Has had active infections requiring oral anti-infection treatment within 2 weeks before the baseline, or has had severe infections or systemic infections within 4 weeks before the baseline, requires intravenous anti-infection treatment or is hospitalized due to infection, or other chronic, recurrent, active infections that the investigator deems unsuitable for participation in this study;\n6. Has active tuberculosis (TB) or latent TB infection;\n7. Has human immunodeficiency virus antibody (HIV) positive at screening, or hepatitis C virus (HCV) antibody positive and further HCV-RNA quantitative positive; or hepatitis B surface antigen (HBsAg) positive; or HBsAg negative but HBcAb positive, and further HBV-DNA test positive; or Treponema pallidum specific antibody positive.\n8. Has severe, progressive, uncontrolled cardiovascular, liver, kidney, lung, gastrointestinal, hematopoietic system, endocrine, nervous system, mental system (such as depression, suicidal tendency and psychological disorders), skin and mucous membrane diseases, and other conditions that the investigator considers that the patient is not suitable to join this trial;\n9. Laboratory tests and\u002For 12-lead electrocardiogram (ECG) results are abnormal at screening:\n\nGeneral situation:\n\n1. Pregnant or lactating women;\n2. Allergic to any component of the test drug;\n3. Had a history of alcohol abuse or illegal drug use within the previous year before the screening;\n4. Had blood donation of approximately 500 mL within the previous 8 weeks before randomization or had a blood donation plan during the study;\n5. Had major surgery within the previous 8 weeks before screening, or had related surgery plans during the study;\n6. The investigator judges that there are other situations that affect the safety and efficacy evaluation of the test drug.","ALL","18 Years",{"count":20,"type":21},60,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","This study is a randomized, double-blind, multi-center, parallel, phase II clinical trial, aiming to evaluate the efficacy and safety of SHR-1139 injection for adult patients with psoriasis. The trial includes a 4-week screening period, a 52-week treatment period, and a 12-week safety follow-up period. Approximately 60 patients with psoriasis are expected to participate.",[27],"Psoriasis","RECRUITING","2026-08-19",{"date":31,"type":32},"2026-08-20","ACTUAL",{"date":34,"type":32},"2026-08-04",{"date":36,"type":21},"2027-10-31",{"name":38,"class":39},"Guangdong Hengrui Pharmaceutical Co., Ltd","INDUSTRY",1,{"id":42,"slug":43,"hasResults":12,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":51,"phases":4,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":54,"startDateStruct":56,"completionDateStruct":58,"leadSponsor":60,"locationsCount":40},"100650390","a-study-of-guselkumab-given-after-ustekinumab-in-participants-with-moderate-to-severe-psoriasis-in-routine-clinical-practice-100650390","NCT07746583","A Study of Guselkumab Given After Ustekinumab in Participants With Moderate to Severe Psoriasis in Routine Clinical Practice","A Non-Interventional, Multi-Centric, Single Country Observational Study to Assess the Safety and Effectiveness of Guselkumab After Ustekinumab (Originator or Biosimilar) in Moderate to Severe Psoriasis Patients in Clinical Routine","G-START","Inclusion criteria:\n\n* Must have a confirmed diagnosis of moderate-to-severe plaque psoriasis requiring systemic treatment\n* Participants who are currently being treated with Ustekinumab (either the originator or its biosimilar) and who are medically indicated to switch to Guselkumab, or for whom this switch is medically indicated, based on the current and valid national psoriasis (PsO) therapeutic protocol\n* Participants who, based on the Investigator's decision, should initiate treatment with Guselkumab\n* Participants must sign an informed consent form (ICF) allowing for data collection and source data verification in accordance with local requirements\n\nExclusion criteria:\n\n* Contraindication or hypersensitivity to Guselkumab or any other ingredient in the injection solution\n* Pregnancy or breastfeeding\n* Currently enrolled in an interventional study\n* Currently enrolled in an observational study sponsored or managed by a Janssen company\n* Previous use of guselkumab in any indication in participant history",{"count":50,"type":21},100,"OBSERVATIONAL","The main purpose of this study is to describe how well Guselkumab works after switching from Ustekinumab in participants with moderate to severe psoriasis in a routine clinical setting. A long-term skin disease that causes red, scaly and sometimes painful, itchy patches on the skin.",[27],{"date":55,"type":32},"2026-08-05",{"date":57,"type":21},"2026-08-07",{"date":59,"type":21},"2029-02-07",{"name":61,"class":39},"Janssen-Cilag Kft.",{"id":63,"slug":64,"hasResults":12,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":4,"eligibilityCriteria":68,"healthyVolunteers":12,"sex":17,"minAge":69,"maxAge":4,"enrollmentInfo":70,"targetDuration":4,"studyType":22,"phases":72,"briefSummary":73,"conditions":74,"keywords":4,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":76,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":4},"100563786","phase-2-a-study-to-investigate-the-efficacy-and-safety-profile-of-gm-xantho-gm-xan003-in-patients-with-psoriasis-100563786","NCT06620692","A Study to Investigate the Efficacy and Safety Profile of GM-XANTHO [GM-XAN003] in Patients With Psoriasis","A Phase IIa Study to Investigate the Efficacy and Safety Profile of GM-XANTHO [GM-XAN003] in Patients With Psoriasis","Inclusion Criteria:\n\n1. Female or male patients are ≥ 20 years old.\n2. Patients who are able to understand the nature of this study and accept to enter the study by signing written informed consent.\n3. Patients are willing or able to comply with procedures required in this protocol including self-administration of study drug.\n4. Patients who have well diagnosed chronic plaque psoriasis for at least 6 months before the Screening Visit (according to Am Fam Physician. 2013 May 1;87(9):626-633).\n5. The severity of plaque psoriasis is stable mild to moderate which meets the following disease activity criteria at both Screening and Baseline Visit (according to Joint AAD-NPF Guidelines)\n6. Patients who agree discontinuation of systemic corticosteroids and systemic immune modulating agents during the study period.\n7. Patients who agree discontinuation of all local treatment modalities, including but not limited to topical corticosteroid or light treatments during the study period for\u002Fon the affected regions.\n8. Patients are required to stop using treatment modalities listed in Criteria #6 and #7 at least 14 days (or longer if the treatment half-life requires so; 7 half-life should have elapsed).\n9. Patients have adequate hematopoietic, hepatic function, and renal function as assessed by the following laboratory requirements to be conducted within 7 days prior to screening:\n\n   * Hemoglobin ≥ 10 g\u002FdL\n   * Total WBC ≥ 3,000 cells\u002FμL\n   * Platelet ≥ 55,000 counts\u002FμL without transfusion support\n   * Total bilirubin ≤ 1.5× ULN and no sign of jaundice\n   * ALT and AST ≤ 5× ULN and no clinical significance\n   * Creatinine ≤ 1.5× ULN and no clinical significance\n10. All male patients and female patients with child-bearing potential (between puberty and 2 years after menopause) should use at least any one of the appropriate contraception methods shown below, for during and at least 4 weeks after GM-XANTHO \\[GM-XAN003\\] treatment.\n\n    1. Total abstinence \\[when this is in line with the preferred and usual lifestyle of the subject. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception\\].\n    2. Female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy) or tubal ligation at least six weeks before taking study treatment. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment.\n    3. Male sterilization. For female subjects on the study, the vasectomized male partner should be the sole partner for that subject.\n    4. Combination of any two of the following listed methods: (d.1+d.2 or d.1+d.3, or d.2+d.3):\n\n    d.1 Use of oral, injected or implanted hormonal methods of contraception or other forms of hormonal contraception that have comparable efficacy (failure rate \\<1%), for example hormone vaginal ring or transdermal hormone contraception.\n\n    d.2 Placement of an intrauterine device (IUD) or intrauterine system (IUS). d.3 Barrier methods of contraception: Condom or Occlusive cap (diaphragm or cervical\u002Fvault caps) with spermicidal foam\u002Fgel\u002Ffilm\u002Fcream\u002Fvaginal suppository.\n\nExclusion Criteria:\n\n1. Patients with the following subtype of psoriasis\n\n   * Erythrodermic psoriasis\n   * Generalized or localized pustular psoriasis,\n   * edication-induced or medication-exacerbated psoriasis,\n   * New onset guttate psoriasis.\n2. Patients who have any concurrent skin condition that will interfere with assessment of treatment.\n3. Patients who have systemic infection during the last 2 weeks prior to Screening Visit or active infection on the psoriasis lesion.\n4. Patients who have known hypersensitivity to the study medication.\n5. Patients with chronic condition(s) which either is not stable or not well controlled.\n6. Patients having positive results for HBV, HCV or HIV screens.\n7. Patients who are pregnant or breast feeding.\n8. Patients who have the medical history of malignancy of any organ system (other than cervical carcinoma in situ or successfully treated non-melanoma skin cancer) within 5 years prior to study entry.\n9. Patients had participated in investigational drug trials and took any investigational drugs within 30 days or within 5 half-life of the investigational drugs prior to the screening visit.\n10. Patients who are not suitable to participate in the trial as judged by the Investigator(s).","20 Years",{"count":71,"type":21},65,[24],"This trial is a Phase IIa clinical trial. Around 65 subjects will be enrolled into this study to primarily assess the treatment efficacy of 5% GM-XANTHO in patients with psoriasis, as well as the safety and tolerability of 5% GM-XANTHO. Two third of the total subjects will be given the investigational product, 5% GM-XANTHO, and the other third will take placebo. The treatment period will last for 28 consecutive days, followed by a safety follow-up for 2 weeks. During the study, there will be 8 scheduled visits to the clinical center.",[27],"NOT_YET_RECRUITING",{"date":57,"type":32},{"date":78,"type":21},"2026-10-01",{"date":80,"type":21},"2028-06-30",{"name":82,"class":39},"Xantho Biotechnology Co., LTD",{"id":84,"slug":85,"hasResults":12,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":4,"eligibilityCriteria":89,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":90,"enrollmentInfo":91,"targetDuration":93,"studyType":51,"phases":4,"briefSummary":94,"conditions":95,"keywords":4,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":40},"100630955","an-ai-based-erythema-measurement-system-for-psoriasis-lesions-100630955","NCT07494396","An AI-Based Erythema Measurement System for Psoriasis Lesions","Development and Validation of an AI-Based Erythema Measurement System for Psoriasis Lesions Using Smartphone Imaging With Color Card Compared to Standard Color Calibration Device","Inclusion Criteria:\n\n* Adults aged ≥18 years\n* Diagnosed with psoriasis by a dermatologist\n* Presence of at least five clearly photographable lesions\n* Willing and able to take photographs using a smartphone with both a standard color calibration card and a study-specific color card at home weekly, and submit images via Line or email\n* Willing to have clinical photographs taken at baseline and at a follow-up visit\n* Provides written informed consent to participate in the study\n\nExclusion Criteria:\n\n* Presence of skin infection or other lesions that may interfere with color assessment (e.g., tattoos)\n* Use of self-tanning products or substances that alter skin color\n* Inability to perform photography or comply with study procedures","100 Years",{"count":92,"type":21},50,"12 Weeks","Psoriasis is a common chronic inflammatory skin disease. Disease severity is commonly assessed using the Psoriasis Area and Severity Index (PASI), in which erythema is graded subjectively on a 0-4 scale. This visual assessment is prone to significant inter- and intra-rater variability.\n\nAlthough objective tools such as colorimeters provide accurate erythema measurement, their high cost limits routine clinical use. Smartphone imaging combined with artificial intelligence (AI) offers a practical alternative for objective assessment. However, variability in lighting conditions can affect image consistency. Incorporating a color calibration card enables accurate color normalization.\n\nThis study aims to develop and validate an AI-based system for measuring erythema in psoriatic lesions using smartphone images with a color card, compared against a standard colorimeter to assess validity and reliability.",[27],"2026-08-03",{"date":55,"type":32},{"date":99,"type":21},"2026-11-01",{"date":101,"type":21},"2027-04-20",{"name":103,"class":104},"Khon Kaen University","OTHER",{"id":106,"slug":107,"hasResults":12,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":4,"eligibilityCriteria":111,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":112,"targetDuration":4,"studyType":22,"phases":114,"briefSummary":116,"conditions":117,"keywords":118,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":122,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":40},"100623037","assessing-psoriasis-treatment-outcomes-100623037","NCT07391423","Assessing Psoriasis Treatment Outcomes","Assessing Psoriasis Treatment Outcomes: a Single-center, Prospective Study Evaluating Patient Outcomes in Psoriasis","Inclusion Criteria:\n\n* Patients ≥18 years of age\n* Patients with a current diagnosis of psoriasis suitable for treatment with topical Betamethasone (BD)\n* Patients who live in the United States\n* Patients with a sufficient command of the English language\n* Patients with a mobile device able to at least operate at 25 frames per second (FPS).\n\nExclusion Criteria:\n\n* Patients less than the age of 18\n* Patients with severe or unstable comorbid conditions\n* Patient who are pregnant or breastfeeding\n* Patients with any other skin conditions that prohibit or confound the ability of the investigator to interpret skin findings\n* Patients that are taking concomitant topical or systemic therapy for the treatment of psoriasis and\u002For phototherapy\n* Patients without mobile devices able to at least operate at 25 frames per second (FPS).\n* Patients without a current diagnosis of psoriasis suitable for treatment with topical BD",{"count":113,"type":21},15,[115],"NA","To assess the feasibility of AIGPP video interactions with psoriasis patients. To explore patient attitudes, trust, and comfort levels concerning AIGPP interactions in a healthcare setting, and to understand their influence on the patient-physician dynamic. To evaluate medication adherence over a 4-week period in patients with psoriasis randomized to weekly AI-generated automated physician providers (AIGPP) video interactions, weekly human video calls, or standard care (single follow up visit after 4 weeks). Adherence rates will be evaluated via a cap designed to record adherence attached to the study medication container.",[27],[119,120,121],"Psoriasis Treatment Outcomes","medication adherence","Artificial intelligence",{"date":34,"type":32},{"date":124,"type":21},"2026-10",{"date":126,"type":21},"2029-03",{"name":128,"class":104},"Wake Forest University Health Sciences",{"id":130,"slug":131,"hasResults":12,"nctId":132,"briefTitle":133,"officialTitle":134,"acronym":4,"eligibilityCriteria":135,"healthyVolunteers":12,"sex":17,"minAge":136,"maxAge":137,"enrollmentInfo":138,"targetDuration":4,"studyType":22,"phases":139,"briefSummary":140,"conditions":141,"keywords":142,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":152,"startDateStruct":153,"completionDateStruct":154,"leadSponsor":156,"locationsCount":40},"100649619","anti-inflammatory-diet-with-physical-therapy-on-psoriasis-100649619","NCT07736651","Anti Inflammatory Diet With Physical Therapy on Psoriasis","Efficacy of an Anti Inflammatory Diet Combined With Physical Therapy on Disease Severity and Inflammatory Markers in Children With Psoriasis","Inclusion Criteria\n\n1. Confirmed diagnosis of plaque psoriasis by a board-certified dermatologist for at least six months prior to enrollment.\n2. Age between 6 and 17 years (inclusive) at the time of enrollment.\n3. Mild to moderate disease severity, defined as a Pediatric Psoriasis Area and Severity Index (P-PASI) score ≤ 20 at the screening visit.\n4. Stable psoriasis treatment regimen (topical or systemic) for at least eight weeks prior to the baseline assessment. Participants may continue their usual treatments throughout the study.\n5. Ability to comply with the dietary protocol (gluten-free, low-histamine anti-inflammatory diet) and, for Group C, the physical therapy program, as judged by the investigator.\n6. Written informed consent from a parent or legal guardian.\n7. Written assent from the child (for participants aged 8-17 years). For children aged 6-7 years, verbal assent will be documented.\n8. Ability to attend all scheduled study visits at the outpatient clinics of Cairo University.\n\nExclusion Criteria\n\n1. Known celiac disease or confirmed wheat allergy (documented by prior diagnostic testing).\n2. Current use of anticoagulant medications or systemic corticosteroids.\n3. Presence of other chronic inflammatory or autoimmune diseases that could confound the results (e.g., juvenile idiopathic arthritis, inflammatory bowel disease, systemic lupus erythematosus).\n4. Severe obesity defined as body mass index (BMI) greater than the 99th percentile for age and sex, which would limit participation in physical activity.\n5. Mental, behavioral, or developmental disorders that would prevent the child from cooperating with the dietary or physical therapy interventions or completing the assessments.\n6. Participation in another interventional clinical trial within the previous three months prior to enrollment.\n7. Any acute illness at the time of recruitment (e.g., febrile illness, acute infection, or acute exacerbation of psoriasis requiring immediate medical intervention).\n8. Known intolerance or allergy to multiple foods included in the diet (e.g., fish, nuts, or other common food allergens) that would make it difficult to adhere to the dietary protocol.\n9. Receiving any investigational drug or biologic therapy for psoriasis within the previous three months.\n10. Concurrent participation in another weight loss or exercise program that would interfere with the study interventions.","6 Years","17 Years",{"count":20,"type":21},[115],"Purpose and Hypotheses The purpose of this study is to find out if changing the diet and adding exercise can help children with psoriasis. Psoriasis is a skin condition that causes red, scaly patches and is linked to inflammation inside the body. We want to see if a special diet that avoids gluten and foods high in histamine can improve children's skin and reduce inflammation. We will also test if adding a fun physical therapy program with light exercise, stretching, and relaxation provides even more benefits, especially for their overall well-being and quality of life.\n\nStudy Details:\n\nStudy Duration: 14 weeks in total (this includes a 2-week screening period and the 12-week treatment period).\n\nTreatment Duration: 12 weeks.\n\nVisit Frequency: Participants will come to the clinic for assessments at the start of the study, after 6 weeks, and after 12 weeks. During the 12-week treatment period, participants in the exercise group will attend supervised physical therapy sessions three times a week.\n\nWhat Will Happen in the Study? Sixty (60) children aged 6 to 17 with mild to moderate psoriasis will be invited to take part. They will be put into one of three groups by chance, like drawing lots. One group will continue with their regular skin care. A second group will follow a special anti-inflammatory diet. This means they will avoid foods with gluten (like wheat bread) and foods high in histamine (like aged cheese or fermented foods) and will eat more fruits, vegetables, and healthy fish. A third group will follow the same diet and also take part in a physical therapy program three times a week. The physical therapy will include light exercise, fun movement activities, and relaxation exercises.\n\nWho Can Participate?\n\nWe are looking for children who:\n\nHave been diagnosed with plaque psoriasis for at least 6 months.\n\nHave mild to moderate psoriasis.\n\nAre not taking any new psoriasis medications.\n\nStudy Interventions:\n\nDietary Intervention: A structured anti-inflammatory diet that is gluten-free and low in histamine.\n\nPhysical Therapy: A supervised program of low-impact aerobic activities, stretching, and relaxation exercises.\n\nThis study is not currently available through an expanded access program.",[27],[143,144,145,146,147,148,149,150],"Anti inflammatory diet","gluten free","low histamine","physical therapy","psoriasis","children","inflammation","quality of life","2026-08-01",{"date":34,"type":32},{"date":151,"type":32},{"date":155,"type":21},"2026-10-31",{"name":157,"class":104},"Mahmoud Usama Mahmoud Ahmed",{"id":159,"slug":160,"hasResults":12,"nctId":161,"briefTitle":162,"officialTitle":163,"acronym":4,"eligibilityCriteria":164,"healthyVolunteers":165,"sex":17,"minAge":18,"maxAge":166,"enrollmentInfo":167,"targetDuration":4,"studyType":51,"phases":4,"briefSummary":169,"conditions":170,"keywords":174,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":177,"startDateStruct":178,"completionDateStruct":180,"leadSponsor":182,"locationsCount":40},"100428886","metabolic-profiling-of-immune-responses-in-immune-mediated-diseases-100428886","NCT04864886","Metabolic Profiling of Immune Responses in Immune-mediated Diseases","Metabolic Profiling of Immune Responses in Immune-Mediated Diseases","* INCLUSION CRITERIA:\n\nIn order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\n1. Meets one of the following:\n\n   1. Has documentation of PID confirmed by genetic evaluation demonstrating a deleterious variant in the gene (or genes) known to be associated with immune deficiency (confirmed PID); or\n   2. Has documented variant of undetermined significance in a gene (or genes) that is predicted to be deleterious in immune function by the investigators OR a clinical history of infections which are more frequent, more chronic, or more severe than normal (suspected PID); or\n   3. Has physician-diagnosed psoriasis; or\n   4. Has physician-diagnosed AD; or\n   5. Does not have clinically apparent evidence of any monogenic or digenic immune defect, AD, or psoriasis (healthy volunteers).\n2. Aged 18 to 75 years.\n3. Willing to allow storage of blood, biopsy tissue, bacterial and fungal cultures, and any other samples collected for future research.\n4. Able to provide informed consent.\n\nEXCLUSION CRITERIA:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n1. Current or prior (within 3 months) anticoagulant or anti-platelet therapy (other than aspirin or non-steroidal anti-inflammatory drugs).\n2. Current or prior (within 3 months) use of immunomodulatory drugs (eg, chemotherapy, steroids), except if approved by the principal investigator.\n3. History of keloid formation.\n4. Pregnancy, lactating, or breastfeeding.\n5. Any condition that, in the opinion of the investigator, contraindicates participation in the study.\n\nCo-enrollment guidelines: Participants may be co-enrolled in other studies; however, study staff should be notified of co-enrollment.",true,"75 Years",{"count":168,"type":21},300,"Background:\n\nThe immune system is the part of the body that fights infection. Some people have immune deficiencies that cause skin rashes, make them get sick often with infections, or make it difficult for their skin to heal. Researchers want to learn more to better treat conditions that affect immune response.\n\nObjective:\n\nTo learn about how the immune system and skin healing are related to each other.\n\nEligibility:\n\nPeople ages 18-75 with primary immune deficiency, eczema, or psoriasis. Healthy volunteers are also needed.\n\nDesign:\n\nParticipants will be screened with a medical and medicine history and a physical exam. They may take a pregnancy test.\n\nParticipants will discuss the medicines or supplements they take as well as skin products they use, such as soaps and lotions.\n\nParticipants will have up to 4 skin biopsies taken from the forearm. A needle will inject an anesthetic into the skin where the biopsy will be done. A sharp tool that looks like a tiny cookie cutter will be used to remove a round plug of skin a bit smaller than the tip of a pencil.\n\nParticipants will give at least 1 blood sample.\n\nParticipants may have optional skin swab collection. A cotton swab will be used to swab the skin on the arm.\n\nParticipants may have optional skin tape collection. A sticky strip of tape will be placed on the arm and then removed.\n\nParticipants may give leftover samples taken as part of their regular medical care.\n\nParticipation will last for about 4 days. Participants will have 2 visits that each last about 1 hour. They may be asked to repeat the study in the future.",[171,27,172,173],"Primary Immunodeficiency","Atopic Dermatitis","Immune-mediated Diseases",[171,27,172,175,176],"pathways","Natural History",{"date":34,"type":32},{"date":179,"type":32},"2021-08-10",{"date":181,"type":21},"2027-06-30",{"name":183,"class":184},"National Institute of Allergy and Infectious Diseases (NIAID)","NIH",{"id":186,"slug":187,"hasResults":12,"nctId":188,"briefTitle":189,"officialTitle":190,"acronym":4,"eligibilityCriteria":191,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":192,"targetDuration":4,"studyType":51,"phases":4,"briefSummary":193,"conditions":194,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":195,"lastUpdatePostDateStruct":196,"startDateStruct":198,"completionDateStruct":199,"leadSponsor":201,"locationsCount":40},"100646339","nailfold-capillaroscopic-changes-in-psoriasis-100646339","NCT07693595","Nailfold Capillaroscopic Changes in Psoriasis","Nailfold Capillaroscopic Changes in Psoriasis and Its Correlation With Disease Severity","Inclusion Criteria:\n\n* Patients clinically diagnosed with psoriasis.\n\nExclusion Criteria:\n\n* Patients with connective tissue diseases (e.g., systemic sclerosis, SLE)\n* Diabetes mellitus or peripheral vascular disease\n* Current smokers\n* Pregnant or lactating women\n* Recent use of vasodilators or beta-blockers\n* Manual workers exposed to vibrating tools",{"count":50,"type":21},"The goal of this observational study is to evaluate nailfold capillaroscopic changes in patients with psoriasis and to assess their correlation with disease severity. The study will also explore differences in capillaroscopic findings across different clinical types of psoriasis and skin phototypes (Fitzpatrick classification). The study will include patients diagnosed with psoriasis attending dermatology outpatient clinics. Participants will undergo clinical assessment and nailfold capillaroscopy to detect microvascular changes.",[27],"2026-07-30",{"date":197,"type":32},"2026-07-31",{"date":151,"type":21},{"date":200,"type":21},"2026-12-01",{"name":202,"class":104},"Al-Azhar University",{"id":204,"slug":205,"hasResults":12,"nctId":206,"briefTitle":207,"officialTitle":208,"acronym":4,"eligibilityCriteria":209,"healthyVolunteers":12,"sex":210,"minAge":18,"maxAge":4,"enrollmentInfo":211,"targetDuration":4,"studyType":22,"phases":213,"briefSummary":215,"conditions":216,"keywords":4,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":195,"lastUpdatePostDateStruct":220,"startDateStruct":221,"completionDateStruct":222,"leadSponsor":224,"locationsCount":40},"100642162","phase-4-a-study-to-assess-concentration-of-tremfya-in-breast-milk-of-lactating-women-who-are-receiving-tremfya-therapeutically-100642162","NCT07654751","A Study to Assess Concentration of TREMFYA in Breast Milk of Lactating Women Who Are Receiving TREMFYA Therapeutically","CNTO1959ISD4001: A Phase 4, Open-Label, Milk-Only Lactation Study to Assess Concentration of TREMFYA in Breast Milk of Lactating Women Who Are Receiving TREMFYA Therapeutically","Inclusion criteria:\n\n* Has an active diagnosis of at least one approved indication for guselkumab (psoriasis, psoriatic arthritis \\[PsA\\], UC and CD) as confirmed by medical records\n* Be medically stable on the basis of medical history review performed at screening. Any abnormalities must be consistent with the underlying illness in the study population and this determination must be recorded in the participant's source documents and initialed by the investigator\n* Currently is on established guselkumab maintenance therapy, that is, has received at least 2 guselkumab subcutaneous (SC) maintenance doses before Day 1\n* Has made the decision to be treated with guselkumab and to breastfeed independently prior to the participant consenting to participate in this study\n* Must be at least 5 weeks postpartum on Day 1\n* Have well-established lactation; participant must be exclusively breastfeeding their infant(s) (or not providing more than 1 supplemental bottle of formula\u002Fday) when enrolled in the study\n* Must plan to continue breastfeeding throughout the duration of the study\n\nExclusion criteria\n\n* Has any current or previous illness that, in the opinion of the investigator, might confound the results of the study or that could prevent, limit, or confound the protocol specified assessments\n* Has history of drug or alcohol abuse according to the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-V) criteria within 1 year before screening\n* Uses or has used an investigational drug (including investigational vaccines) or used an invasive investigational medical device within 1 month before enrolling in the study\n* Has received or plans to receive any live, attenuated vaccine within 12 weeks prior to administration of guselkumab. Non-live vaccines approved or authorized for emergency use (for example, Coronavirus disease-19 \\[COVID-19\\]) by local health authorities are allowed\n* Has a positive urine pregnancy test on Day 1","FEMALE",{"count":212,"type":21},10,[214],"PHASE4","The purpose of this post-marketing study is to assess the amount of guselkumab in breast milk of lactating women receiving guselkumab as part of their standard clinical care provided by their treating physician, for any of the approved indications.",[27,217,218,219],"Colitis, Ulcerative","Crohn Disease","Arthritis, Psoriatic",{"date":197,"type":32},{"date":78,"type":21},{"date":223,"type":21},"2027-08-31",{"name":225,"class":39},"Janssen Research & Development, LLC",{"id":227,"slug":228,"hasResults":12,"nctId":229,"briefTitle":230,"officialTitle":231,"acronym":4,"eligibilityCriteria":232,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":233,"targetDuration":4,"studyType":22,"phases":234,"briefSummary":236,"conditions":237,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":195,"lastUpdatePostDateStruct":250,"startDateStruct":251,"completionDateStruct":253,"leadSponsor":255,"locationsCount":257},"100348403","phase-1-testing-an-immunotherapy-anti-cancer-drug-nivolumab-for-advanced-cancers-in-patients-with-autoimmune-disorders-aim-nivo-100348403","NCT03816345","Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO","A Phase Ib Study of Nivolumab in Patients With Autoimmune Disorders and Advanced Malignancies (AIM-NIVO)","Inclusion Criteria:\n\n* Patients can have either histologically confirmed malignancy that is radiologically evaluable and metastatic or unresectable, or have a malignancy for which a PD-1\u002FPD-L1 inhibitor has been approved in the adjuvant setting, as well as the neoadjuvant or perioperative setting in which such treatment is considered standard of care or has been approved. Eligible tumor types include solid tumors and malignancies in which there is known evidence of clinical activity for single agent PD-1 or PD-L1 antibodies. Nivolumab or other PD1\u002FPD-L1 inhibitors are FDA-approved for the treatment of melanoma, non-small cell lung cancer (NSCLC), Merkel cell cancer, bladder cancer, renal cell carcinoma (RCC), gastric cancer, hepatocellular carcinoma (HCC), cervical cancer, head and neck cancer, Hodgkin lymphoma (HL), metastatic small cell lung cancer (SCLC), and any solid tumor with microsatellite instability (MSI)-high status confirmed. Patients with HL are eligible but must follow standard response criteria. Additional tumor types may be eligible on a case by case basis upon discussion with principal investigator (PI)\n\n  * Patients enrolling on the trial for adjuvant use will be restricted to those with histology for which a PD-1\u002FPD-L1 inhibitor has been approved in the adjuvant setting including but not limited to NSCLC, melanoma, RCC, cervical cancer, and bladder cancer\n  * Patients enrolled on the study can receive Nivolumab with other FDA-approved combinations according to the FDA package insert, including, but not limited to ipilimumab, cabozantinib or chemotherapy\n* Patients who have previously received other forms of immunotherapy (high-dose \\[HD\\] IL-2, IFN, CTLA-4) are allowed. Patients must not have received cytokine immunotherapy for at least 4 weeks before nivolumab administration. Patients who have received prior anti-CTLA4 will be allowed and the washout period is 6 weeks\n* Age \\>= 18 years; children are excluded from this study but may be eligible for future pediatric phase 1 combination trials\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 (Karnofsky \\>= 60)\n* Life expectancy of greater than 12 weeks\n* Leukocytes \\>= 1,000\u002FmcL\n* Absolute neutrophil count \\>= 500\u002FmcL\n* Platelets \\>= 50,000\u002FmcL\n* Total bilirubin =\\\u003C 2 x institutional upper limit of normal (ULN)\n* Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase \\[SGOT\\])\u002Falanine aminotransferase (ALT) (serum glutamate pyruvate transaminase \\[SGPT\\]) =\\\u003C 5 x institutional ULN or =\\\u003C 8 x institutional ULN for patients with liver metastases or an autoimmune disease that is contributing to the elevation of these values\n* Creatinine ULN OR glomerular filtration rate (GFR) \\>= 30 mL\u002Fmin (if using the Cockcroft-Gault formula)\n* Human immunodeficiency virus (HIV)-infected patients on effective antiretroviral therapy with undetectable viral load within 6 months are eligible for this trial\n* If evidence of chronic hepatitis B virus (HBV) infection, HBV viral load must be undetectable on suppressive therapy if indicated\n* If history of hepatitis C virus (HCV) infection, must be treated with undetectable HCV viral load\n* Patients with new or progressive brain metastases (active brain metastases) or leptomeningeal disease are eligible if the treating physician determines that immediate central nervous system (CNS) specific treatment is not required and is unlikely to be required for at least 4 weeks (or scheduled assessment after the first cycle of treatment), and a risk-benefit analysis (discussion) by the patient and the investigator favors participation in the clinical trial\n* The effects of nivolumab on the developing human fetus are unknown. For this reason, women of child-bearing potential (WOCBP) and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. WOCBP receiving nivolumab will be instructed to adhere to contraception for a period of 5 months after the last dose of investigational product. Men receiving nivolumab and who are sexually active with WOCBP will be instructed to adhere to contraception for a period of 7 months after the last dose of investigational product\n\n  * Women of childbearing potential must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU\u002FL or equivalent units of human chorionic gonadotropin \\[HCG\\]) within 24 hours prior to the start of nivolumab. Women must not be breastfeeding. Women who are not of childbearing potential (i.e., who are postmenopausal or surgically sterile as well as azoospermic men) do not require contraception\n  * WOCBP is defined as any female who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy), tubal ligation, or who is not postmenopausal. Menopause is defined clinically as 12 months of amenorrhea in a woman over 45 in the absence of other biological or physiological causes. In addition, women under the age of 55 must have a documented serum follicle stimulating hormone (FSH) level less than 40 mIU\u002FmL\n  * These durations have been calculated using the upper limit of the half-life for nivolumab (25 days) and are based on the protocol requirement that WOCBP use contraception for 5 half-lives plus 30 days, and men who are sexually active with WOCBP use contraception for 5 half-lives plus 90 days\n  * Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she (or the participating partner) should inform the treating physician immediately. Patients can resume treatment upon termination of a pregnancy or the completion of a successful pregnancy\n* Ability to understand and the willingness to sign a written informed consent document\n* Patients with more than one autoimmune disease are eligible. The treating physician would determine which autoimmune disease is dominant and the patient would be treated under that specific cohort (Please note: Patients with more than one autoimmune disease should receive assessments for all previously diagnosed autoimmune diseases. For example, a patient with psoriasis and IBD might be enrolled in the IBD cohort. Disease assessments for both psoriasis and IBD should be obtained, as per protocol. Case report forms \\[CRFs\\] for all relevant autoimmune diseases should be utilized. However, all additional cohort requirements will be considered optional and only the assessments from the assigned cohort will be considered mandatory)\n* DM\u002FSSc-SPECIFIC INCLUSION: Patients with known SSc or DM according to updated classification criteria (Van den Hoogan et al., Arthritis Rheum 2013;65(11):2737-47; Lundberg et al., A\\&R in press). Overlap features are permitted, but patients must meet criteria for a \"primary diagnosis\" of DM or SSc\n* DM\u002FSSc-SPECIFIC INCLUSION: Patients may be on any concurrent therapy for DM or SSc unless specifically excluded\n* DM\u002FSSc-SPECIFIC INCLUSION: Patients must have a baseline computed tomography (CT) of the chest (within 6 months of study entry)\n* RA-SPECIFIC INCLUSION: Rheumatologist-diagnosed RA requiring prior treatment with disease-modifying antirheumatic drugs (DMARDs) before patient was diagnosed with current malignancy. We recommend, but do not require, documentation for meeting 2010 American College of Rheumatology (ACR)\u002FEuropean League Against Rheumatism (EULAR) classification criteria for RA\n* RA-SPECIFIC INCLUSION: Prednisone up to 10 mg\u002Fday will be allowed. Intraarticular steroids will be allowed for the treatment of new symptomatic joints\n* RA-SPECIFIC INCLUSION: Nonsteroidal anti-inflammatory drugs (NSAIDs) will be allowed\n* SLE-SPECIFIC INCLUSION: SLE diagnosed by a rheumatologist. The patient should meet the revised 1997 American College of Rheumatology (ACR) classification criteria for SLE, but this is not mandatory\n* ULCERATIVE COLITIS (UC)-SPECIFIC INCLUSION: Diagnosis of UC must be made by endoscopy with biopsies\n* UC-SPECIFIC INCLUSION: Complete colonoscopy with biopsies during study screening, within 8 weeks before initial nivolumab administration, or within 4 weeks after initial nivolumab administration\n* UC-SPECIFIC INCLUSION: Patients must test negative for hepatitis B (antigen \\[Ag\\] negative, antibody \\[core (c)Ab\\] negative, antibody \\[surface (s)Ab\\] positive or negative) and Mycobacterium tuberculosis (purified-protein- derivative \\[PPD\\] or enzyme-linked immunospot assay \\[ELISpot or T-spot\\]) or be on appropriate anti-microbial treatment for these infections\n* UC-SPECIFIC INCLUSION: Mild Disease Cohort: Patients must be in clinical remission, defined as a Mayo Clinic score (MCS) of 2 or lower and no subscore higher than 1, and an endoscopic subscore of 0 or 1 either without medications, or treated with 5-ASA derivative, probiotic, or prior fecal transplant\n* UC-SPECIFIC INCLUSION: Moderate Disease Cohort: Patients must be in clinical remission, defined as a MCS of 2 or lower and no subscore higher than 1, and an endoscopic subscore of 0 or 1 on 6-mercaptopurine, azathioprine, methotrexate, or rectal hydrocortisone, budesonide, or one of these medications in combination with any of the medications listed in the Mild cohort\n* UC-SPECIFIC INCLUSION: Severe Disease Cohort (A or B): Patients must either be A) in clinical remission, defined as a MCS of 2 or lower and no subscore higher than 1, and an endoscopic subscore of 0 or 1 on a biologic therapy targeting tumor necrosis alpha (TNF-α) (infliximab, adalimumab, golimumab), α4β7 integrin (vedolizumab), or one of these biologic therapies in combination with any of the medications listed in the Mild or Moderate cohort, or B) have mild active disease defined as a MCS of 3-5 and no subscore higher than 2, and an endoscopic subscore of \\\u003C 2 on one of the medications or combination of medications defined for the Moderate or Mild cohort\n* CROHN'S DISEASE (CD)-SPECIFIC INCLUSION: Complete colonoscopy with biopsies during study screening, within 8 weeks before initial nivolumab administration, or within 4 weeks after initial nivolumab administration\n* CD-SPECIFIC INCLUSION: If patients have prior known disease in the stomach or small intestines, appropriate endoscopic evaluation (esophagogastroduodenoscopy\u002Fvideo capsule endoscopy) and\u002For imaging (computed tomography or magnetic resonance enterography) must also be current within 4 weeks prior to nivolumab administration\n* CD-SPECIFIC INCLUSION: Deep enteroscopy techniques, such as double balloon enteroscopy, will not be required\n* CD-SPECIFIC INCLUSION: Patients must test negative for hepatitis B (sAg negative, cAb negative, sAb positive or negative) and M. tuberculosis (PPD or ELISpot or T-spot) or be on appropriate anti-microbial treatment for these infections\n* CD-SPECIFIC INCLUSION: Mild Disease Cohort: Patients must be in clinical remission as defined by a Crohn's Disease Activity Index (CDAI) \\\u003C 150 either without treatment or on a 5-ASA derivative, probiotic, antibiotics, or following fecal transplant\n* CD-SPECIFIC INCLUSION: Moderate Disease Cohort: Patients must be in clinical remission as defined by a CDAI \\\u003C 150 on 6-mercaptopurine, azathioprine, methotrexate, rectal hydrocortisone, budesonide, or one of these medications in combination with any of the medications listed in the Mild cohort\n* CD-SPECIFIC INCLUSION: Severe Disease Cohort (A or B): Patients must either A) be in clinical remission as defined by a CDAI \\\u003C 150 on biologic therapy targeting TNF-α (infliximab, adalimumab, certolizumab pegol), IL-12\u002F23p40 (ustekinumab), α4β7 integrin (vedolizumab), or one of these biologic therapies in combination with any of the medications listed in the Mild or Moderate cohort, or B) have mild active disease as defined by a CDAI of 150 to 220 on one of medications or combination of medications defined for the Moderate or Mild cohort\n* OTHER AUTOIMMUNE DISEASES- NS-SPECIFIC INCLUSION: For other autoimmune diseases that cannot be classified, the eligibility criteria will be determined by the managing rheumatologist or other autoimmune disease specialist, based on the clinical judgement and current American College of Radiology (ACR) classification guidelines or other relevant guidelines, as per the disease category in question\n* OTHER AUTOIMMUNE DISEASES- NS-SPECIFIC INCLUSION: For giant cell arteritis (GCA), patients must have had positive temporal artery biopsy for GCA and abnormal erythrocyte sedimentation rate (ESR) at time of diagnosis\n* OTHER AUTOIMMUNE DISEASES- NS-SPECIFIC INCLUSION: For polymyalgia rheumatica (PMR), patients must have clinical diagnosis in addition to elevated inflammatory markers including (ESR, C reactive protein \\[CRP\\])\n* OTHER AUTOIMMUNE DISEASES- NS-SPECIFIC INCLUSION: Patients can be in remission (with no glucocorticoids or immunosuppressive medications) or have low-moderate activity, which is defined as being on prednisone ≤ 10 mg or equivalent\n* MS-SPECIFIC INCLUSION: Patients must meet 2017 McDonald criteria for the diagnosis of MS (Thompson AJ, et al. Diagnosis of multiple sclerosis: 2017 revision of the McDonald criteria. Lancet Neurol. 17(2):162-173.)\n* MS-SPECIFIC INCLUSION: Patients with MS can be in remission and can have a history of being on immunomodulatory agents, but at the time of entry into the clinical trial, patients should be off any concurrent MS therapy for at least 2 weeks. Patients receiving concomitant interferon gamma (IFN-γ treatment) will be permitted in the study\n* SJS-SPECIFIC INCLUSION: SjS diagnosed by a rheumatologist or oral medicine provider. The patient should meet the American-European Consensus Criteria for Sjögren's Syndrome (Vitali, et al., 2002). If on treatment, the patient may only be on hydroxychloroquine and prednisone ≤ 10 mg or equivalent\n* PSO\u002FPSA-SPECIFIC INCLUSION: Patients with known PsO as diagnosed by a dermatologist or PsA by a rheumatologist and\u002For by Classification for Psoriatic Arthritis (CASPAR) criteria (Tillett et al., 2012)\n* PSO\u002FPSA-SPECIFIC INCLUSION: Patients must have stable disease as determined by the investigator with no change in systemic therapy and\u002For biologic therapy for at least 3 months, except for those on tumor necrosis factor (TNF) inhibitors. In the case of TNF inhibition, patients may have transitioned to an alternative biologic therapy with stable disease for at least 4 weeks. For PsA, no change in corticosteroid therapy for at least 1 month prior to baseline and dose must be 10 mg or less\n* PSO\u002FPSA-SPECIFIC INCLUSION: Patients may be on any concurrent therapy for PsO or PsA unless specifically excluded\n\nExclusion Criteria:\n\n* Patients who have had chemotherapy or radiotherapy within 2 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events (AEs) due to agents administered more than 4 weeks earlier have not resolved or stabilized. Palliative (limited-field) radiation therapy (RT) is permitted (2 week washout from start of treatment), if all of the following criteria are met:\n\n  * Repeat imaging demonstrates no new sites of bone metastases\n  * The lesion being considered for palliative radiation is not a target lesion\n* Patients with prior therapy with an anti-PD-1 or anti-PD-L1\n* Patients with prior allogeneic hematologic transplant\n* Patients who are receiving any other anticancer investigational agents\n* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements\n* UC-SPECIFIC EXCLUSION: Patients who have received ipilimumab treatment\n* UC-SPECIFIC EXCLUSION: Prior colectomy\n* UC-SPECIFIC EXCLUSION: Concurrent primary sclerosing cholangitis (PSC). Patients with PSC can be enrolled on the Other Autoimmune Diseases Cohorts\n* UC-SPECIFIC EXCLUSION: Patients on empiric immunosuppressive treatment without any clinical workup\n* CD-SPECIFIC EXCLUSION: Known untreated abscesses, untreated and symptomatic strictures, short gut physiology, or isolated jejunal disease\n* CD-SPECIFIC EXCLUSION: Patients who have received ipilimumab treatment\n* CD-SPECIFIC EXCLUSION: Patients on empiric immunosuppressive treatment without any clinical workup\n* MS-SPECIFIC EXCLUSION: Patients with MS cannot have medical contraindications to gadolinium-enhanced magnetic resonance imaging (MRI)",{"count":168,"type":21},[235],"PHASE1","This phase Ib trial studies the side effects of nivolumab and to see how well it works alone and in combination with other treatments, such as ipilimumab, cabozantinib, platinum containing therapy, and fluoropyrimidine, in treating patients with autoimmune disorders and cancer that has spread from where it first started (primary site) to nearby tissue, lymph nodes, or distant parts of the body (advanced), to other places in the body (metastatic) or cannot removed by surgery (unresectable). Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Cabozantinib blocks certain proteins, which may help keep tumor cells from growing. It may also prevent the growth of new blood vessels that tumors need to grow. Cabozantinib is a type of tyrosine kinase inhibitor and a type of angiogenesis inhibitor. Chemotherapy drugs, such as platinum containing therapies and fluoropyrimidine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving nivolumab alone and in combination with other treatments, including ipilimumab, cabozantinib, platinum containing therapy, or fluoropyrimidine, may be safe, tolerable, and\u002For effective in treating patients with autoimmune disorders and advanced, metastatic, or unresectable cancer.",[238,218,239,240,241,242,243,27,244,245,246,247,248,249],"Autoimmune Disease","Dermatomyositis","Hematopoietic and Lymphoid Cell Neoplasm","Inflammatory Bowel Disease","Malignant Solid Neoplasm","Multiple Sclerosis","Psoriatic Arthritis","Rheumatoid Arthritis","Sjogren Syndrome","Systemic Lupus Erythematosus","Systemic Scleroderma","Ulcerative Colitis",{"date":197,"type":32},{"date":252,"type":32},"2019-07-16",{"date":254,"type":21},"2028-03-30",{"name":256,"class":184},"National Cancer Institute (NCI)",52,{"id":259,"slug":260,"hasResults":12,"nctId":261,"briefTitle":262,"officialTitle":263,"acronym":4,"eligibilityCriteria":264,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":166,"enrollmentInfo":265,"targetDuration":4,"studyType":22,"phases":267,"briefSummary":269,"conditions":270,"keywords":4,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":271,"lastUpdatePostDateStruct":272,"startDateStruct":274,"completionDateStruct":276,"leadSponsor":278,"locationsCount":280},"100648816","phase-3-a-clinical-trial-of-tqh3906-capsules-in-adult-patients-with-moderate-to-severe-plaque-psoriasis-100648816","NCT07724366","A Clinical Trial of TQH3906 Capsules in Adult Patients With Moderate to Severe Plaque Psoriasis","A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Multicenter Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of TQH3906 Capsules in the Treatment of Adult Patients With Moderate to Severe Plaque Psoriasis","Inclusion Criteria:1. Participants must be between 18 and 75 years old when signing the informed consent form (ICF), regardless of gender; 2. Confirmed diagnosis of plaque psoriasis for at least 6 months at screenin 3. Disease is stable at screening and baseline visits, and the following criteria are met:\n\n* Static Physician Global Assessment (sPGA) score ≥3;\n* Psoriasis Area and Severity Index (PASI) score ≥12;\n* Body Surface Area (BSA) affected by psoriasis ≥10%; 4. Deemed by the Investigator as suitable for systemic therapy or phototherapy; 5. Women of childbearing potential must have a negative pregnancy test at screening and baseline visits. Women of childbearing potential and male trial participants whose spouse or partner is a woman of childbearing potential must be willing to use at least one effective method of contraception as specified in the protocol during the study period (from signing the ICF until 30 days after the last dose of investigational drug). Male trial participants must also commit to not donating sperm during the study period and within 30 days after the last dose of study drug; 6. Before initiating any screening or study-specific procedures, trial participants must be able to understand and willing to comply with all protocol requirements, and voluntarily sign and date the ICF.\n\nExclusion Criteria:1.Presence of non-plaque psoriasis during the Screening period or at the Baseline visit; 2.Past or current diagnosis of drug-induced psoriasis; 3.Concomitant other autoimmune diseases, including but not limited to rheumatoid arthritis, sarcoidosis, and systemic lupus erythematosus; 4.Receiving therapeutic agents for psoriatic arthritis (PsA) other than stable-dose non-steroidal anti-inflammatory drugs (NSAIDs) or analgesics.\n\n5.Prior exposure to TQH3906 Capsules or Deucravacitinib Tablets; 6.Receipt of any of the following medications or treatments within the specified time window:\n\n1. Any topical agents or treatments that may interfere with psoriasis assessment, administered within 2 weeks before the Baseline visit;\n2. Psoriasis phototherapy administered within 4 weeks before the Baseline visit;\n3. Any biologics or biosimilars thereof, administered within the specified time frame before the Baseline visit;\n4. Systemic non-biologic psoriasis therapy and\u002For systemic immunosuppressive treatment administered within 4 weeks before the Baseline visit; 5) Within 6 months prior to the baseline visit: Leflunomide; 6) Within 4 weeks prior to the baseline visit: Traditional Chinese medicines (TCM), Chinese proprietary medicines, or herbal preparations used for psoriasis treatment or with unknown composition\u002Fnature, including but not limited to Total Glucosides of Paeony, Tripterygium wilfordii preparations, Compound Glycyrrhizin preparations, Compound Qingdai preparations, etc.; 7) Within 4 weeks prior to the baseline visit: Any live vaccines or live-attenuated vaccines; OR anticipated need to receive live vaccines or live-attenuated vaccines during the study period including at least 4 weeks after the last dose of investigational product; 8) Within 3 months prior to the baseline visit (or 5 half-lives, whichever is longer): Investigational biological agent treatment; OR within 30 days prior to the baseline visit (or 5 half-lives, whichever is longer): Any other investigational drug treatment; OR currently participating in other clinical trials; 7. Active infection\u002Fhistory of infection, or receipt of specific anti-infective therapies within the specified time windows; 8. Previous or current presence of severe or unstable diseases or medical conditions involving neurological, cardiovascular, respiratory, digestive, urinary, hematological, or immune systems that, in the Investigator's judgment, may interfere with outcome assessment or affect participation safety 9. Laboratory test abnormalities meeting any of the following criteria during the screening period: 1) Hemoglobin \\\u003C90.0 g\u002FL; 2) White blood cell count \\\u003C3.0×10⁹\u002FL; 3) Neutrophil count \\\u003C1.0×10⁹\u002FL; 4) Lymphocyte count \\\u003C0.5×10⁹\u002FL; 5) Platelet count \\\u003C100×10⁹\u002FL; 6) Alanine aminotransferase (ALT) and\u002For Aspartate aminotransferase (AST) \\>3× Upper Limit of Normal (ULN); 7) Total bilirubin (TBIL) \\>1.5× ULN; 8) Estimated creatinine clearance \\\u003C45 mL\u002Fmin calculated based on the Cockcroft-Gault formula. (See Appendix 2 for calculation formula); 9) Thyroid-stimulating hormone (TSH) outside the normal reference range, concomitant with free T4 or T3 also outside the normal reference range.\n\n10\\. History of drug or alcohol abuse within 6 months prior to screening; 11. Known allergy, hypersensitivity, or intolerance to TQH3906 capsules, deucravacitinib tablets, or any excipient ingredients; 12. Women who are pregnant, breastfeeding, or planning to become pregnant during the trial, and men who plan to father children or donate sperm during the trial; 13. Trial participants who are employees of the Sponsor, third-party agency staff, or direct research center staff involved in this study or their family members; 14. Per Investigator assessment, presence of any other medical, psychiatric, or other reasons that render the trial participant unsuitable for participation in this study.\n\n\\-",{"count":266,"type":21},400,[268],"PHASE3","This study is a multicenter, randomized, double-blind, placebo- and active-controlled Phase III clinical trial sponsored by Nanjing Shunxin Pharmaceutical Co., Ltd., a subsidiary of Chiatai Tianqing Pharmaceutical Group. The study aims to evaluate the efficacy and safety of once-daily oral TQH3906 capsules (24 mg) in adult participants with moderate to severe plaque psoriasis. TQH3906 is a highly selective TYK2 allosteric inhibitor targeting the JH2 domain, which blocks the IL-23 and Type I interferon inflammatory pathways. Approximately 400 eligible participants aged 18-75 years will be enrolled. Participants will be stratified based on prior biologic use and randomized in a 2:2:1 ratio to the TQH3906 group, the deucravacitinib active control group, or the placebo group. The trial includes a screening period, a 16-week double-blind controlled treatment phase, a 36-week open-label extension phase (during which all participants will receive TQH3906), and a 4-week safety follow-up after the last dose. The co-primary endpoints are the proportion of participants achieving sPGA 0\u002F1 and PASI 90 response at Week 16. Secondary endpoints include improvements in scalp, nail, and palmoplantar psoriasis, Dermatology Life Quality Index (DLQI), long-term safety, and steady-state pharmacokinetic parameters. This study will collect comprehensive efficacy and safety data over 52 weeks to support the New Drug Application (NDA) for TQH3906 for the treatment of plaque psoriasis.",[27],"2026-07-21",{"date":273,"type":32},"2026-07-24",{"date":275,"type":21},"2026-08",{"date":277,"type":21},"2028-06",{"name":279,"class":39},"Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.",43,{"id":282,"slug":283,"hasResults":12,"nctId":284,"briefTitle":285,"officialTitle":286,"acronym":4,"eligibilityCriteria":287,"healthyVolunteers":165,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":288,"targetDuration":4,"studyType":51,"phases":4,"briefSummary":290,"conditions":291,"keywords":293,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":296,"lastUpdatePostDateStruct":297,"startDateStruct":298,"completionDateStruct":299,"leadSponsor":301,"locationsCount":4},"100641821","evaluation-of-serum-il-41-level-in-patients-with-ankylosing-spondylitis-and-psoriatic-arthritis-100641821","NCT07648836","Evaluation of Serum IL-41 Level in Patients With Ankylosing Spondylitis and Psoriatic Arthritis","Evaluation of Serum IL-41 Level in Patients With Ankylosing Spondylitis and Psoriatic Arthritis and Their Association With Inflammatory Markers and Disease Activity","Inclusion Criteria:\n\n* patients diagnosed with ankylosing spondylitis (AS)and psoriatic arthritis (PsA), in addition to age- and sex-matched healthy controls.\n\nAS diagnosed according to the modified New York criteria, while PsA was diagnosed based on the CASPAR criteria.\n\nExclusion Criteria:\n\nPatients under the age of 18 years, patients with other autoimmune diseases, diabetes mellitus, chronic kidney or liver disease, active infection, or malignancy were excluded to avoid confounding factors affecting inflammatory markers.",{"count":289,"type":21},90,"Psoriatic arthritis (PsA) and ankylosing spondylitis (AS) are chronic inflammatory diseases within the spectrum of spondyloarthritis, characterized by immune-mediated inflammation and progressive functional impairment. Meteorin-like protein (Metrnl) is a novel adipomyokine with potential immunomodulatory and anti-inflammatory properties; however, its role in spondyloarthritis remains incompletely understood. This study aims to evaluate serum Metrnl levels in patients with PsA and AS compared with healthy controls and to investigate their association with disease activity, inflammatory markers, and clinical manifestations. The findings may provide insights into the potential role of Metrnl as a biomarker of disease activity and inflammation in spondyloarthritis.",[292,27],"Ankylosing Spondylitis",[294,147,295],"Ankylosing spondylitis","biomarker","2026-07-19",{"date":271,"type":32},{"date":78,"type":21},{"date":300,"type":21},"2026-12-30",{"name":302,"class":104},"Assiut University",{"id":304,"slug":305,"hasResults":12,"nctId":306,"briefTitle":307,"officialTitle":308,"acronym":4,"eligibilityCriteria":309,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":310,"enrollmentInfo":311,"targetDuration":4,"studyType":22,"phases":313,"briefSummary":314,"conditions":315,"keywords":316,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":319,"lastUpdatePostDateStruct":320,"startDateStruct":322,"completionDateStruct":324,"leadSponsor":326,"locationsCount":40},"100647787","phase-4-combined-fractional-co-laser-and-topical-corticosteroid-versus-topical-corticosteroid-only-in-the-treatment-of-palmoplantar-psoriasis-100647787","NCT07713212","Combined Fractional CO₂ Laser and Topical Corticosteroid Versus Topical Corticosteroid Only in the Treatment of Palmoplantar Psoriasis","Comparative Study of the Efficacy and Safety of Combined Fractional CO₂ Laser and Topical Corticosteroid Versus Topical Corticosteroid Only in the Treatment of Palmoplantar Psoriasis: A Pilot Randomized Controlled Clinical Trial","Inclusion criteria\n\n* Adults aged ≥18 years\n* Stable psoriasis\n* Confirmed cases of palmoplantar psoriasis (with or without psoriasis elsewhere) dermoscopically(Hand \\_held dermoscopy) and histopathologically if required.\n* Willingness to comply with treatment and follow-up\n* Written informed consent obtained\n\nExclusion criteria:\n\n* Other palmoplantar dermatoses (eczema, tinea, keratoderma)\n* Generlized Pustular psoriasis\n* Erythrodermic psoriasis\n* Use of:\n\n  * Systemic antipsoriatic therapy within 3 months\n  * Biologic therapy within 12 weeks\n  * Topical treatment on palms\u002Fsoles within 2 weeks\n* Pregnancy or lactation\n* History of photosensitivity disorders","60 Years",{"count":312,"type":21},32,[214],"To assess whether adding fractional laser to topical corticosteroid improves treatment outcomes in palmoplanter psoriasis compared to topical corticosteroid alone.",[27],[147,317,318],"fractional CO2 laser","topical treatment","2026-07-14",{"date":321,"type":32},"2026-07-20",{"date":323,"type":21},"2026-08-15",{"date":325,"type":21},"2027-02-15",{"name":327,"class":104},"Cairo University",{"id":329,"slug":330,"hasResults":12,"nctId":331,"briefTitle":332,"officialTitle":333,"acronym":4,"eligibilityCriteria":334,"healthyVolunteers":165,"sex":17,"minAge":335,"maxAge":4,"enrollmentInfo":336,"targetDuration":4,"studyType":51,"phases":4,"briefSummary":338,"conditions":339,"keywords":341,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":343,"lastUpdatePostDateStruct":344,"startDateStruct":345,"completionDateStruct":347,"leadSponsor":349,"locationsCount":40},"100375572","skin-microbial-ecology-in-atopic-dermatitis-100375572","NCT04170244","Skin Microbial Ecology in Atopic Dermatitis","Longitudinal \"Real-World\" Changes in Skin Microbial Ecology in Atopic Dermatitis (AD) and Psoriasis (PS) Patients","Inclusion Criteria:\n\n* ≥13 to 65 years of age (inclusive) for PS, ≥13 for AD and NA, male or female\n* Optional Bx sub study - only adults (18-65 yrs; inclusive only)\n* Able to understand protocol and give consent\n* Able to keep clinic\u002Fstudy appointments and comply with study related procedures\n* Must be able to read, speak, and understand English\n* Chronic AD, according to the American Academy of Dermatology (AAD) Consensus Criteria (Eichenfield 2014), that has been present for at least 1 year before the enrollment visit\n* Chronic PS, according to the AAD Consensus Criteria (Menter et al 2008 (section 1)), that has been present for at least 1 year before the enrollment visit.\n* AD subjects: have active lesions on upper extremities, lower extremities, or trunk and a total disease severity of high moderate-to-severe (EASI ≥12)\n* PS subjects: have active lesions on upper extremities, lower extremities, or trunk and a total disease severity of high moderate-to-severe (PASI ≥7)\n\nExclusion Criteria:\n\n* Unwilling and\u002For unable to complete informed consent process\n* \\\u003C13 or \\> 65 years of age for PS, \\>13 for AD and NA\n* AD subjects: disease without upper extremity, lower extremity, or trunk lesions\n* AD subjects: total disease severity less than moderate (EASI \\\u003C12), depending on enrollment\n* PS subjects: disease without upper extremity, lower extremity, or trunk lesions\n* PS subjects: total disease severity less than moderate (PASI \\\u003C7), depending on enrollment\n* Control subjects: diagnosed with an inflammatory skin disease\n* Severe concomitant illness(es) that, in the investigator's judgment, would adversely affect the individual's participation in the study (Ex: HIV infection, autoimmune disease, severe heart failure, Hx of malignancy (other than in situ cervical cancer or basosquamous skin cancer), etc.)\n* Recent bacterial, fungal, or viral infection requiring systemic therapies (PO, IV or IM) within the last month.\n* Subjects with a history of serious life-threatening reaction to tape or adhesives may be enrolled but cannot undergo Tape stripping procedure and will therefore only have a baseline TEWL measurement.\n* (For Skin biopsy substudy only) - Subjects with history of keloid formation or allergy to lidocaine.","13 Years",{"count":337,"type":21},240,"Everybody's skin has bacteria that normally lives on it. Previous research has shown that people with eczema (or atopic dermatitis \\[AD\\]) have much higher concentrations of a certain bacteria (S. aureus), especially when their disease is active but little is known about the role that this bacteria plays in psoriasis (i.e. disease severity, biomarkers and skin barrier function). The overarching purpose of this longitudinal study is to understand how the abundance of skin S. aureus (and several commensal bacteria) change as a consequence of standard of care treatment in the URMC dermatology clinics. Other assays and biospecimens will also be collected to address a number of questions.",[172,27,340],"Healthy",[342],"staphylococcus, microbiome, atopic dermatitis, cutibacterium","2026-07-12",{"date":319,"type":32},{"date":346,"type":32},"2019-04-17",{"date":348,"type":21},"2027-04-01",{"name":350,"class":104},"University of Rochester",{"id":352,"slug":353,"hasResults":12,"nctId":354,"briefTitle":355,"officialTitle":355,"acronym":356,"eligibilityCriteria":357,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":358,"targetDuration":4,"studyType":51,"phases":4,"briefSummary":360,"conditions":361,"keywords":362,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":371,"lastUpdatePostDateStruct":372,"startDateStruct":374,"completionDateStruct":376,"leadSponsor":377,"locationsCount":40},"100607381","sequential-treatment-of-psoriasis-with-biologics-100607381","NCT07187817","SEquential Treatment of PSoriasis With Biologics","STEPS","Inclusion Criteria:\n\n* Diagnosis of chronic plaque psoriasis by a Dermatology consultant\n* Prior treatment with biologic or targeted synthetic treatment (1 to 10 lines) for psoriasis in the United Kingdom\n\nExclusion Criteria:\n\n* Diagnosis of other forms of psoriasis for example generalised pustular psoriasis",{"count":359,"type":21},366,"Psoriasis is a common skin condition that leads to patches of scaled skin which can be inflamed, sore and itchy. It can affect any area of skin on the body, as well as nails, and can be widespread and severe. Over the past 20 years, many new treatments have been developed and approved for severe psoriasis. Most of these newer treatments are given by injection and, as a group, are known as biologics. Many people respond well to biologics and have a meaningful improvement in their condition. There is a smaller proportion of people who do not respond well, or develop side effects, and so must switch drugs to try and improve their condition. In some cases, people need multiple lines of biologic treatment. Currently very little is understood about how well people respond when they are treated with three or more biologics in a row, as very few trials have been done in these cases.\n\nThis study aims to use data from people who have already been treated with biologics by their Dermatology teams in the NHS and use the information obtained during their normal clinic appointments to investigate this question. The investigators will assess how well people respond to each line of biologic drug (1st to 10th). They will look at whether people respond as well or less well over time, the more biologics they have. People can be included in the research if they are 18 or over and have been treated with a biologic for psoriasis in participating hospitals in the NHS in England. In this study the investigators are assessing data from events that have previously happened, and so no extra visits are required",[27],[363,364,365,366,367,368,369,370],"biologic","bdmard","tsdmard","biological agent","3rd line","4th line","switch","cycle","2026-07-08",{"date":373,"type":32},"2026-07-09",{"date":375,"type":32},"2025-10-14",{"date":57,"type":21},{"name":378,"class":104},"Royal United Hospitals Bath NHS Foundation Trust",{"id":380,"slug":381,"hasResults":12,"nctId":382,"briefTitle":383,"officialTitle":384,"acronym":385,"eligibilityCriteria":386,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":387,"enrollmentInfo":388,"targetDuration":4,"studyType":22,"phases":390,"briefSummary":391,"conditions":392,"keywords":393,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":395,"lastUpdatePostDateStruct":396,"startDateStruct":397,"completionDateStruct":399,"leadSponsor":401,"locationsCount":403},"100630608","phase-2-a-study-to-evaluate-d-2570-in-participants-with-moderate-to-severe-plaque-psoriasis-100630608","NCT07489885","A Study to Evaluate D-2570 in Participants With Moderate to Severe Plaque Psoriasis","A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Study to Evaluate the Efficacy and Safety of D-2570 in Participants With Moderate to Severe Plaque Psoriasis","N\u002FZ","Inclusion Criteria:\n\n* Participants with a diagnosis of plaque psoriasis with no significant flares of disease activity for at least 6 months before signing the informed consent\n* Participants have moderate to severe plaque psoriasis as defined by a total body surface area (BSA) ≥10%, a Psoriasis Area and Severity Index (PASI) score ≥ 12 and a Physician's Global Assessment (PGA) score ≥ 3.\n* Within normal ranges of laboratory assessments\n\nExclusion Criteria:\n\n* Any comorbidities or past medical conditions as outlined in the protocol that would interfere with study assessments as deemed by the Investigator","70 Years",{"count":389,"type":21},75,[24],"A Study looking at the safety and efficacy of D-2570 in Participants with Plaque Psoriasis",[27],[394],"Moderate to Severe Plaque Psoriasis","2026-07-07",{"date":373,"type":32},{"date":398,"type":32},"2026-06-03",{"date":400,"type":21},"2027-12",{"name":402,"class":39},"InventisBio Co., Ltd",20,{"id":405,"slug":406,"hasResults":12,"nctId":407,"briefTitle":408,"officialTitle":409,"acronym":410,"eligibilityCriteria":411,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":412,"targetDuration":4,"studyType":51,"phases":4,"briefSummary":414,"conditions":415,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":416,"lastUpdatePostDateStruct":417,"startDateStruct":419,"completionDateStruct":421,"leadSponsor":423,"locationsCount":424},"100641889","a-study-of-persistence-to-guselkumab-treatment-in-participants-with-moderate-to-severe-plaque-psoriasis-in-romania-100641889","NCT07582783","A Study of Persistence to Guselkumab Treatment in Participants With Moderate-to-Severe Plaque Psoriasis in Romania","Persistence to Treatment With Guselkumab in Bio-Naive Patients With Moderate-to-Severe Plaque Psoriasis: A Romanian Non-Interventional Multi-center Observational Study","PROGRESS-RO","Inclusion criteria:\n\n* Has a confirmed diagnosis of moderate-to-severe plaque psoriasis\n* Participant must sign an informed consent form allowing source data verification in accordance with local requirements\n* Is able to read, understand, and complete the patient reported outcomes (PRO) instruments in local language and comply with completion of all PRO instruments\n* No previous exposure to biological treatment, including guselkumab (bio-naive patient)\n* Intended for the treatment with guselkumab according to the approved indication\n\nExclusion criteria:\n\n* Meets any of the contraindications according to the latest version of the locally approved summary of product characteristics (SmPC)\n* Is pregnant or lactating\n* Current or recent (in the last 30 days prior to first SC dose of guselkumab) participation in any interventional study with investigational product.\n* Currently enrolled in another observational study sponsored or managed by a Johnson \\& Johnson company",{"count":413,"type":21},200,"This study aims to assess the proportion of participants with moderate-to-severe plaque psoriasis who continue treatment with guselkumab over a two-year period.",[27],"2026-07-02",{"date":418,"type":32},"2026-07-06",{"date":420,"type":32},"2026-05-15",{"date":422,"type":21},"2028-11-10",{"name":225,"class":39},19,{"id":426,"slug":427,"hasResults":12,"nctId":428,"briefTitle":429,"officialTitle":429,"acronym":4,"eligibilityCriteria":430,"healthyVolunteers":12,"sex":17,"minAge":431,"maxAge":4,"enrollmentInfo":432,"targetDuration":4,"studyType":22,"phases":434,"briefSummary":435,"conditions":436,"keywords":441,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":455,"lastUpdatePostDateStruct":456,"startDateStruct":458,"completionDateStruct":460,"leadSponsor":462,"locationsCount":4},"100629926","a-randomised-controlled-trial-of-eprom-guided-flexible-scheduling-in-dermatology-100629926","NCT07481019","A Randomised Controlled Trial of ePROM-Guided Flexible Scheduling in Dermatology","Inclusion Criteria:\n\n* Dermatology outpatients otherwise due for a follow-up appointment within six months.\n* Ability to independently navigate and complete ePROMs.\n* Ability to provide informed consent (including parental consent for minors).\n\nExclusion Criteria:\n\n* Patients who require fixed or scheduled in-person visits, including those needing skin cancer surveillance, bedside procedures (e.g., liquid nitrogen therapy), surgical interventions, or routine blood tests for immunosuppressive therapy.","16 Years",{"count":433,"type":21},250,[115],"The goal of this clinical trial is to evaluate whether an electronic patient-reported outcome measure (ePROM)-guided flexible scheduling system can improve outpatient clinic resource utilisation in patients attending dermatology outpatient clinics for routine follow-up. The main questions it aims to answer are:\n\n* Does the intervention reduce the number of actualised outpatient visits over 12 months compared with standard fixed scheduling?\n* Does the intervention group achieve higher adherence to monthly ePROM monitoring, as measured by the proportion of completed ePROM submissions?",[437,438,439,27,440],"Chronic Dermatological Conditions","Eczema","Urticaria","Acne",[442,443,444,445,446,447,448,449,450,451,452,453,454],"dermatology","flexible scheduling","patient initiated follow up","electronic patient-reported outcomes","ePROMs","Bayesian decision support","outpatient care","health services research","randomised controlled trial","implementation science","healthcare utilisation","appointment no-shows","value-based care","2026-06-29",{"date":457,"type":32},"2026-07-01",{"date":459,"type":21},"2026-09",{"date":461,"type":21},"2029-12",{"name":463,"class":104},"National University Hospital, Singapore",{"id":465,"slug":466,"hasResults":12,"nctId":467,"briefTitle":468,"officialTitle":469,"acronym":4,"eligibilityCriteria":470,"healthyVolunteers":12,"sex":17,"minAge":431,"maxAge":4,"enrollmentInfo":471,"targetDuration":4,"studyType":22,"phases":473,"briefSummary":474,"conditions":475,"keywords":476,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":455,"lastUpdatePostDateStruct":483,"startDateStruct":484,"completionDateStruct":486,"leadSponsor":488,"locationsCount":40},"100570057","use-of-a-digital-psychotherapeutic-app-to-reduce-symptom-burden-in-dermatology-patients-100570057","NCT06702293","Use of a Digital Psychotherapeutic App to Reduce Symptom Burden in Dermatology Patients","Development and Testing of a Digital Psychological Tool to Improve Symptom Burden in Dermatology Patients","Inclusion Criteria:\n\n* Patients with psoriasis, eczema or chronic urticaria diagnosed by a dermatologist\n* Aged 16 or older\n* Peak pruritus intensity of 4 or more on a 11-point numerical rating scale (0-10, with 10 representing worst itch)\n* Able to engage with a mobile application in the English language\n\nExclusion Criteria:\n\n* Patients with active psychiatric symptoms (e.g. active suicidal ideation, psychosis, delusions)\n* Patients with unstable psychiatric condition, characterized by\n\n  o Hospital inpatient admission for a psychiatric condition or initiation of a psychotropic medication in the prior 3 months\n* Patients with unstable dermatological condition, characterized by\n\n  * Recent flare of the skin condition within the last 2 weeks, including diagnosis of a flare by a doctor, use of systemic steroids, oral antibiotics, wet wrap rescue therapy, oral antivirals, or increase in frequency of phototherapy or dose of systemic medications for the dermatological condition within the last 2 weeks OR\n  * Any of the following within 3 months\n\n    * inpatient admission for a dermatological condition\n    * Initiation of phototherapy\n    * Initiation of systemic therapy (conventional immunosuppressive agent, biologics, JAK inhibitors) within the last 3 months.",{"count":472,"type":21},690,[115],"Skin diseases, despite low mortality, significantly impair quality of life. This randomised controlled trial evaluates the efficacy of a digital toolkit comprising psychotherapeutic strategies in reducing QoL burden in patients with chronic inflammatory skin conditions. This toolkit is hosted on a mobile application and will be used by study participants randomised to the intervention arm over the 32 week study period.",[438,27,439],[477,478,147,479,480,481,482],"digital health","eczema","urticaria","healthservices research","digital","mental health",{"date":457,"type":32},{"date":485,"type":32},"2026-02-23",{"date":487,"type":21},"2029-07",{"name":463,"class":104},{"id":490,"slug":491,"hasResults":12,"nctId":492,"briefTitle":493,"officialTitle":494,"acronym":495,"eligibilityCriteria":496,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":387,"enrollmentInfo":497,"targetDuration":4,"studyType":22,"phases":498,"briefSummary":499,"conditions":500,"keywords":501,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":503,"lastUpdatePostDateStruct":504,"startDateStruct":506,"completionDateStruct":508,"leadSponsor":510,"locationsCount":40},"100608675","phase-2-safety-and-efficacy-of-cbp-0276-to-improve-severity-and-quality-of-life-on-moderate-to-severe-psoriasis-in-subjects-100608675","NCT07204639","Safety and Efficacy of CBP-0276 to Improve Severity and Quality of Life on Moderate to Severe Psoriasis in Subjects","Safety and Efficacy of CBP-0276 200mg\u002FDay Twice Dose a Day, or Placebo Administrated for 36 Weeks, to Improve Severity and Quality of Life on Moderate to Severe Psoriasis in Subjects 18y to 70y: Randomized Controlled Trial","CBP-0276-Pso","Inclusion Criteria:\n\n1. Signed written informed consent\n\n   a. Patients must be willing to participate in the study and sign the informed consent form\n2. Type of patient and target disease characteristics\n\n   1. Men and women, diagnosed with stable plaque psoriasis for 6 months or more. Stable psoriasis is defined as no morphology changes or significant flares of disease activity, in the opinion of the investigator\n   2. Deemed by the investigator to be a candidate for systemic therapy\n   3. ≥10% of body surface area (BSA) involvement at screening visit and Day 1\n   4. Psoriasis Area and Severity Index (PASI) score ≥12, and static Physician's Global Assessment (sPGA) ≥3 at screening visit and Day 1\n3. Age and reproductive status\n\n   1. Men and women aged 18 years to 70 years at the time of screening visit\n   2. Women of childbearing potential (WOCBP) must have a negative serum pregnancy test at screening visit, and a negative urine pregnancy test (minimum sensitivity 25 IU\u002FL or equivalent units of human chorionic gonadotropin within 24 hours prior to the start of study drug\n   3. Women must not be pregnant, lactating, breastfeeding, or planning pregnancy during the study period\n   4. Women of childbearing potential must agree to correctly use a highly effective method(s) of contraception for the duration of treatment plus 30 days (duration of ovulatory cycle) for a total of 33 days post-treatment completion (total of 33 days after last dose of study drug). WOCBP who are continuously not heterosexually active are exempt from contraceptive requirements, but must still undergo pregnancy testing as described in this protocol\n   5. Male patients who are sexually active with WOCBP must agree to follow instructions for method(s) of contraception for the duration of treatment with study treatment(s) plus 5 half-lives of the study treatment (3 days) for a total of 3 days post-treatment completion.\n\n      Additionally, male patients must be willing to refrain from sperm donation during this time\n   6. Investigators shall counsel WOCBP, and male patients who are sexually active with WOCBP, on the importance of pregnancy prevention and the implications of an unexpected pregnancy. Investigators shall advise on the use of highly effective methods of contraception, which have a failure rate of \\\u003C1% when used consistently and correctly.\n\nExclusion Criteria:\n\n1. Use of phototherapy 4 weeks or less prior randomization\n2. Infectious\u002Fimmune-related exclusions\n\n   1. History or evidence of outpatient active infection and\u002For febrile illness within 7 days prior to Day 1\n   2. History of serious bacterial, fungal, or viral infection requiring hospitalization and intravenous antimicrobial treatment within 60 days prior to Day 1\n   3. Any untreated bacterial infection within 60 days prior to Day 1\n   4. Any ongoing evidence of chronic bacterial infection (eg, chronic pyelonephritis, chronic osteomyelitis, chronic bronchiectasis)\n   5. Any history of proven infection of a joint prosthesis in which the prosthesis was not removed or replaced, or received antibiotics for suspected infection of a joint prosthesis in which the prosthesis was not removed or replaced\n   6. Received live vaccines within 60 days prior to Day 1, or plans to receive a live vaccine during the study, or within 60 days after completing study treatment\n   7. Presence of herpes zoster lesions at screening or Day 1\n   8. History of serious herpes zoster or serious herpes simplex infection, which includes, but is not limited to, any episode of disseminated herpes simplex, multidermatomal herpes zoster, herpes encephalitis, ophthalmic herpes, or recurrent herpes zoster (recurrent is defined as 2 episodes within 2 years)\n   9. Evidence of, or positive test for, hepatitis B virus at screening. Positive hepatitis B lab testing is defined as 1) positive hepatitis B surface antigen (HBsAg+) OR 2) presence of hepatitis B virus DNA OR 3) positive anti-hepatitis B core antibody without concurrent positive hepatitis B surface antibody (HBcAb+ and HBsAb-)\n   10. Evidence of, or positive test for, hepatitis C virus (HCV) at screening. A positive test for HCV is defined as: positive for hepatitis C antibody (anti-HCV Ab) AND 2) positive via a confirmatory test for HCV (for example, HCV polymerase chain reaction)\n   11. Positive for human immunodeficiency virus by antibody testing (HIV-1 and -2 Ab) at screening\n   12. Any history of known or suspected congenital or acquired immunodeficiency state or condition that would compromise the patient's immune status (eg, history of opportunistic infections \\[eg, Pneumocystis jirovecii pneumonia, histoplasmosis, or coccidioidomycosis\\], history of splenectomy, primary immunodeficiency)\n3. Any of the following tuberculosis (TB) criteria:\n\n   1. History of active TB prior to screening visit, regardless of completion of adequate treatment\n   2. Signs or symptoms of active TB (eg, fever, cough, night sweats, and weight loss) during screening, as judged by the investigator\n   3. Any imaging of the chest (eg, chest x-ray, chest computed tomography scan) obtained during the screening period, or any time within 6 months prior to screening with documentation, showing evidence of current active or history of active pulmonary TB\n   4. Latent TB infection (LTBI) defined as positive interferon gamma release assay (IGRA), by QuantiFERON-TB Gold testing at screening, in the absence of clinical manifestations\n\n   Note: Patient is eligible if (i) there are no current signs or symptoms of active TB AND (ii) patient has received adequate documented treatment for LTBI within 5 years of screening OR has initiated prophylactic treatment for LTBI per local guidelines and is rescreened after 1 month of treatment. To continue in the study, patient must agree to complete a locally recommended course of treatment for LTBI. Use of rifampin, however, is not recommended as it can reduce efficacy of apremilast used as a comparator in this trial\n\n   Note: An IGRA test that is indeterminate must be retested for confirmation. If the second test is again indeterminate, the patient will be excluded from the study. If the retest is positive, the patient should be treated as having LTBI. If the retest is negative, the patient may be eligible provided no other exclusion criteria for TB are met.\n4. Medical history and concurrent diseases\n\n   1. Any major surgery within 8 weeks prior to Day 1, or any planned surgery for the first 52 weeks of the study\n   2. Has donated blood \\>500 mL within 4 weeks prior to Day 1, or plans to donate blood during the course of the study\n   3. Drug or alcohol abuse, as determined by the investigator, within 6 months prior to Day 1\n   4. Medical marijuana or prescription marijuana taken for medicinal reasons\n   5. Any major illness\u002Fcondition or evidence of an unstable clinical condition (eg, renal, hepatic, hematologic, gastrointestinal, endocrine, pulmonary, psychiatric, neurologic, immunologic, or local active infection\u002Finfectious illness) that, in the investigator's judgment or after consultation with the medical monitor, will substantially increase the risk to the patient if he or she participates in the study\n   6. Unstable cardiovascular disease, defined as a recent clinical cardiovascular event (eg, unstable angina, myocardial infarction, stroke, rapid atrial fibrillation) in the last 3 months prior to screening, or a cardiac hospitalization (eg, revascularization procedure, pacemaker implantation) within 3 months prior to screening\n   7. Has uncontrolled arterial hypertension characterized by a systolic blood pressure (BP) \\>160 mm Hg or diastolic BP \\>100 mm Hg\n\n      Note: Determined by 2 consecutive elevated readings. If an initial BP reading exceeds this limit, the BP may be repeated once after the patient has rested sitting for ≥10 minutes. If the repeat value is less than the criterion limits, the second value may be accepted.\n   8. Class III or IV congestive heart failure by New York Heart Association Criteria\n   9. Has cancer or history of cancer (solid organ or hematologic including myelodysplastic syndrome) or lymphoproliferative disease within the previous 5 years (other than resected cutaneous basal cell or squamous cell carcinoma, or carcinoma of cervix in situ that has been treated with no evidence of recurrence)\n   10. Any uncontrolled psychiatric illness (such as untreated depression, or bipolar disorder) judged as clinically significant by the investigator during screening or at Day 1 OR any lifetime history of suicidal ideation, suicidal behavior, or suicidal attempts by medical history or by electronic Columbia-Suicide Severity Rating Scale (eC-SSRS) documentation, or by answering \"yes\" to Question 4 or 5 for suicidal ideation on the eC-SSRS at screening or at Day 1, or is clinically deemed to have a suicide risk by the investigator\n   11. Prior exposure to investigational product on the last 6 months (ie, deucravacitinib or apremilast)\n   12. If the patient has received biologics previously, the following exclusion criteria for washout will apply: Antibodies to IL-12, IL-17, or IL-23 within 6 months of Day 1 prior randomization; Tumor necrosis factor inhibitor(s) within 2 months of Day 1; Agents that modulate integrin pathways to impact lymphocyte trafficking (eg, natalizumab), or agents that modulate B cells or T cells within 3 months of Day 1; or Rituximab within 6 months of Day 1\n   13. Has received systemic nonbiologic psoriasis medications and\u002For any systemic immunosuppressant therapy, including, but not limited to methotrexate, azathioprine, cyclosporine, Janus kinase inhibitors, mercaptopurine, mycophenolate mofetil, tacrolimus, oral or injectable corticosteroids, retinoids, 1,25-dihydroxy vitamin D3 and analogues within 4 weeks prior to Day 1\n   14. Has used leflunomide within 6 months prior to Day 1\n   15. Has used opioid analgesics within 4 weeks prior to Day 1\n   16. Has received lithium, antimalarials, or intramuscular gold within 4 weeks of the first administration of any study medication\n   17. Has used any strong CYP450 inducers (eg, rifampin, phenobarbital, carbamazepine, phenytoin) within 4 weeks prior to Day 1\n   18. Has used topical medications\u002Ftreatments that could affect psoriasis evaluation (including, but not limited to, high potency corticosteroids (World Health Organization \\[WHO\\] Classes I-V), \\>3% salicylic acid, urea, alpha- or beta-hydroxyl acids, anthralin, calcipotriene, topical vitamin D derivatives, retinoids, tazarotene, methoxsalen, pimecrolimus, and tacrolimus) within 2 weeks prior to Day 1\n\n       Note: Low-potency topical steroids (WHO Class VI and VII) are permitted on the palms, soles, face, and intertriginous areas but should not be used within 24 hours prior to any study visit. Bland emollients (defined as emollients without urea or alpha or beta hydroxy acids or other ingredients that are pharmaceutically active) are allowed on all body regions but should not be used within 24 hours prior to any study visit.\n   19. Use of shampoos containing corticosteroids, coal tar, \\>3% salicylic acid, or vitamin D3 analogues within 2 weeks prior to Day 1\n   20. Has received an experimental antibody or experimental biologic therapy within the previous 6 months OR received any other experimental therapy or new investigational agent within 30 days or 5 half-lives (whichever is longer) prior to Day 1 OR is currently enrolled in an investigational study\n5. Laboratory evaluations\n\n   1. Absolute white blood cell count \\\u003C3000\u002Fmm3\n   2. Absolute lymphocyte count \\\u003C500\u002Fmm3\n   3. Absolute neutrophil count \\\u003C1000\u002Fmm3\n   4. Platelet count \\\u003C100,000\u002Fmm3\n   5. Hemoglobin \\\u003C9 g\u002FdL\n   6. Alanine aminotransferase and\u002For aspartate aminotransferase \\>3 × upper limit of normal (ULN)\n   7. Total, unconjugated, and\u002For conjugated bilirubin \\>2 × ULN\n   8. Thyroid-stimulating hormone outside the normal reference range AND free T4 (thyroxine) or T3 (triiodothyronine) outside the normal reference range\n   9. Electrocardiogram abnormalities that are considered clinically significant and would pose an unacceptable risk to the patient if participating in the study\n   10. Renal impairment based on an estimated glomerular filtration rate \\\u003C45 mL\u002Fmin",{"count":50,"type":21},[24],"Randomized, controlled trial, Proof of Concept, Phase 2 aimed to evaluate the effect of CBP-0276 in dose of 200mg twice dose a day, or placebo administrated for 36 weeks to improve Psoriasis Area and Severity Index (PASI)75 or static Physician's Global Assessment (sPGA) score of 0 or 1; PASI50, PASI90, PASI100, Scalp-specific Physician's Global Assessment (Ss-PGA) 0\u002F1 with at least a 2-point improvement among patients with a baseline ss-PGA ≥3, sPGA 0, PSSD symptom score of 0 among patients with baseline score ≥1, Dermatology Life Quality Index (DLQI) 0\u002F1 at Week 6,12,18,24, 30 and 36 among patients with baseline DLQI ≥2, adjusted by transcriptomics profile (post-hoc analysis), Percentage of subjects which achieve The Minimum Clinically Important Difference (MCID) on DLQI (a ≥4-point reduction from baseline) at Week 4 and 8, Frequency of solicited and unsolicited adverse events (SAEs and USAEs) (Medra), and Changes on inflammatory and anti-inflammatory cytokine levels during treatment (IL-17, IL-23, IL-6, TNF-alpha, IL1-b, IL-10).",[27],[502],"CBP-0276, Randomized trial phase 2, Psoriasis","2026-06-26",{"date":505,"type":32},"2026-06-30",{"date":507,"type":32},"2025-10-01",{"date":509,"type":21},"2026-08-30",{"name":511,"class":39},"Clarent Biopharma, Inc.",{"id":513,"slug":514,"hasResults":12,"nctId":515,"briefTitle":516,"officialTitle":516,"acronym":4,"eligibilityCriteria":517,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":518,"targetDuration":4,"studyType":22,"phases":520,"briefSummary":521,"conditions":522,"keywords":523,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":526,"lastUpdatePostDateStruct":527,"startDateStruct":529,"completionDateStruct":531,"leadSponsor":533,"locationsCount":40},"100560210","use-of-total-body-pet-to-quantify-systemic-and-cutaneous-inflammation-in-psoriasis-patients-before-and-after-intervention-with-a-nutritionally-balanced-diet-100560210","NCT06574178","Use of Total-Body PET to Quantify Systemic and Cutaneous Inflammation in Psoriasis Patients Before and After Intervention With a Nutritionally Balanced Diet","Inclusion Criteria:\n\n* Adults (\\>18 year)\n* Both sexes\n* Must have a history of psoriasis of at least 3% body surface area affected by skin psoriasis (in a body area that the subject will allow the PI to perform several skin biopsies as noted below (optional)) and may carry a diagnosis of psoriatic arthritis as well\n* Patients will have a BMI of \\>\u002F=25 which is consistent with being overweight - Willing and able to fast for at least 6 hours before and for the duration of the scan visit\n* No strenuous exercise for 24 hours prior to being scanned\n* Recruited patients must habitually consume a WD-type diet that will be evaluated by using DHQ III food frequency questionnaire along with three-day food record14. Subsequently, the Healthy Eating Index will be calculated and participants with a poor dietary pattern (score below 58) will be eligible for the study15.\n\nExclusion Criteria:\n\n* Those taking anti-diabetic oral or injected medications\n* Those already ingesting a caloric- or component-restricted diet\n* Vegan, vegetarian or food allergy or intolerance to the ingredients of the diet\n* \\>5% change in body weight in the last 2 months\n* Those taking systemic medications for the purpose of treating psoriasis or psoriatic arthritis for at least 3 months prior to first PET scan or during the duration of the trial\n* Self-reported history of dysphoria or anxiety in closed spaces (claustrophobia)\n* Uncontrolled diabetes or blood glucose level greater than 180 mg\u002Fdl at the time of radiotracer injection\n* Body weight \\>240 kg due to limitations of the scanner bed\n* Known inflammatory or other infectious disease that can confound assessment\n* Pregnant or breast-feeding (urine pregnancy test will be administered prior to start of each PET\u002FCT session for all participants who are able to get pregnant between 18 to 60 years old, unless documented hysterectomy or bilateral ovarian removal is available, because of risks from ionizing radiation)\n* Inability to lie motionless on the scanner bed with the arms by the side for up to 60 minutes\n* Currently participating in another conflicting research study. Concurrent or prior enrollment in a separate research study involving a PET scan performed within the last 12 months for research purposes only.\n* Unwilling to sign informed consent\n* Inability to understand the risks and benefits of the study\n* Prisoners",{"count":519,"type":21},5,[115],"Psoriasis is a chronic inflammatory disease that affects the skin and joints in 2-3 % of people in the United States. This inflammation of the skin, joints, and blood vessels in patients with psoriasis has been measured by older PET Scan technology but with limitations. With the new EXPLORER PET scanner technology, the investigators are testing to see if the EXPLORER is better than previous PET scanners and improve our ability to assess inflammation in patients.\n\nAlso, it is known that the typical Western Diet - high in saturated fats, added sugars, and low in fiber - contributes to obesity and inflammation worldwide. There is evidence in animals that these signs of inflammation are reversible within 4 weeks when changed to a more balanced diet. Thus, this study aims to assess whether there are detectable decreases in inflammation of the skin and body of psoriasis patients who usually eat a Western Diet on an EXPLORER PET scan following 6 weeks of a more balanced diet.",[27],[524,525],"western diet","Total-body PET","2026-06-12",{"date":528,"type":32},"2026-06-16",{"date":530,"type":32},"2025-01-01",{"date":532,"type":21},"2026-09-01",{"name":534,"class":104},"University of California, Davis",{"id":536,"slug":537,"hasResults":12,"nctId":538,"briefTitle":539,"officialTitle":539,"acronym":4,"eligibilityCriteria":540,"healthyVolunteers":165,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":541,"targetDuration":543,"studyType":51,"phases":4,"briefSummary":544,"conditions":545,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":546,"lastUpdatePostDateStruct":547,"startDateStruct":549,"completionDateStruct":551,"leadSponsor":553,"locationsCount":556},"100641842","ppd-corevitas-psoriasis-pso-early-treatment-response-non-interventional-study-100641842","NCT07648602","PPD™ CorEvitas™ Psoriasis (PSO) Early Treatment Response Non-Interventional Study","Inclusion Criteria:\n\nTo be eligible to participate in this study, an individual must meet all the following criteria:\n\n1. Patient is at least 18 years of age at the time of study enrollment.\n2. Patient has a diagnosis of moderate to severe plaque psoriasis based on an investigator Global Assessment (IGA, score of 3 or 4 at the time of Enrollment).\n3. Patient is initiating new Eligible Medication for the first time for the treatment of PSO.\n4. Patient is willing and able to provide informed consent to participate in this study.\n\nExclusion Criteria:\n\nAn individual who meets any of the following criteria will be excluded from participation in the study:\n\n1. Patient is participating in a blinded clinical trial.\n2. Patients that do not receive at least 1 dose of the advanced therapy within 14 days following the Enrollment\u002FBaseline visit for the study.\n3. Patients cannot be concurrently enrolled in both the CorEvitas PSO Registry and the PPDTM CorEvitasTM Psoriasis (PSO) Early Treatment Response Non-Interventional Study. A. Patients currently enrolled in the CorEvitas PSO Registry are ineligible for participation in the PPDTM CorEvitasTM Psoriasis (PSO) Early Treatment Response Non-Interventional Study.\n\nB. Patients otherwise meeting eligibility criteria can be enrolled in the PPDTM CorEvitasTM Psoriasis (PSO) Early Treatment Response Non-Interventional Study C. Following completion or at time of Exit from the PPDTM CorEvitasTM Psoriasis (PSO) Early Treatment Response Non-Interventional Study, patients will be eligible to enroll into the CorEvitas PSO Registry for long term follow-up at the standard of care cadence supported by the registry. A separate Informed consent will be obtained.",{"count":542,"type":21},2500,"26 Weeks","This is a 24-week prospective, single-arm cohort, study of patients initiating advanced therapy for the treatment of moderate-to-severe plaque PSO. Eligible patients must be willing to be seen in-person by their treating physician for a Baseline visit (with first dose of the advanced therapy occurring within 14 days), and at 16 (+\u002F- 5 days) and 24 weeks (+14 days) calculated based on date of first dose of the advanced therapy and must provide informed consent prior to enrolling in the study or completing study-specific questionnaires or procedures. Data will be collected from both subjects and their treating dermatology provider at predetermined scheduled intervals (Baseline, Week 16 and Week 24) using a structured and standardized data collection tool.",[27],"2026-06-11",{"date":548,"type":32},"2026-06-15",{"date":550,"type":21},"2026-06-01",{"date":552,"type":21},"2036-12-31",{"name":554,"class":555},"CorEvitas","NETWORK",2,{"id":558,"slug":559,"hasResults":12,"nctId":560,"briefTitle":561,"officialTitle":562,"acronym":563,"eligibilityCriteria":564,"healthyVolunteers":165,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":565,"targetDuration":4,"studyType":51,"phases":4,"briefSummary":567,"conditions":568,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":578,"lastUpdatePostDateStruct":579,"startDateStruct":580,"completionDateStruct":582,"leadSponsor":584,"locationsCount":40},"100562149","identification-of-cutaneous-and-blood-biomarkers-predictive-of-response-to-systemic-treatments-during-chronic-inflammatory-skin-diseases-100562149","NCT06599411","Identification of Cutaneous and Blood Biomarkers Predictive of Response to Systemic Treatments During Chronic Inflammatory Skin Diseases","Identification Des Marqueurs Biologiques cutanés et Sanguins prédictifs de réponse Aux Traitements systémiques au Cours Des Maladies cutanées Inflammatoires Chroniques","ImmuneSkinBank","Inclusion Criteria:\n\nPatients:\n\n* Age\\>18 years\n* Informed consent signed by the patient\n* Diagnosis of moderate to severe chronic inflammatory skin disease (IGA score 3 or 4) including: atopic dermatitis, psoriasis, hidradenitis suppurativa, lichen planus, cutaneous lupus, dermatomyositis, cutaneous scleroderma (=morphea), neutrophilic dermatosis, cutaneous granulomatosis, cutaneaous vasculitis, autoimmune bullous dermatosis\n* Or diagnosis of active leprosy (tuberculoid, lepromatous, reversion type 1, reversion type 2, hypersensitivity type 3), excluding pure neurological leprosy. Classification into 5 stages according to the Ridley and Jopling classification \\[1\\], Reversion reaction (type 1 reaction) and leprous erythema nodosum (type 2 reaction).\n\nHealthy controls :\n\n* Age\\>18 years\n* Plastic surgery patients who have had any type of surgery resulting in healthy skin remnants\n* Informed consent signed by the patient\n* Absence of known cutaneous inflammatory disease.\n\nExclusion Criteria:\n\n* Under guardianship or curatorship\n* Pregnant or breastfeeding woman\n* Lack of affiliation with a social security system\n* Current systemic treatment with immunosupressant (including corticosteroid therapy) or an immunomodulator or received within the last 3 months.",{"count":566,"type":21},830,"Chronic inflammatory skin diseases constitute a heterogeneous group of pathologies. They affect the skin but also other organs (joints, lungs, muscles, etc.). Their prognosis and response to treatments is extremely variable. The discovery of prognosis factors will help to precisely guide the treatment regimen and its intensification based on individual markers. The identification of new therapeutic targets is essential to develop new innovative treatments for inflammatory skin diseases.\n\nThe main objective is to identify new cellular or molecular prognostic factors associated with treatment response at 1 year in inflammatory skin diseases.\n\nThe secondary objectives are a better understanding of the pathophysiology of chronic inflammatory skin diseases, the identification of new cellular, molecular and microbiological prognostic factors associated with the clinical state after 10 years of evolution and the identification of prognostic markers of drug toxicity.",[172,27,569,570,571,239,572,573,574,575,576,577],"Hidradenitis Suppurativa","Lichen Planus","Cutaneous Lupus","Cutaneaous Scleroderma","Neutrophilic Dermatosis","Cutaneous Granulomatosis","Active Leprosy","Autoimmune Bullous Dermatosis","Cutaneous Vasculitis","2026-06-10",{"date":526,"type":32},{"date":581,"type":32},"2025-10-20",{"date":583,"type":21},"2045-10-20",{"name":585,"class":104},"Assistance Publique - Hôpitaux de Paris",{"id":587,"slug":588,"hasResults":12,"nctId":589,"briefTitle":590,"officialTitle":591,"acronym":4,"eligibilityCriteria":592,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":593,"targetDuration":4,"studyType":51,"phases":4,"briefSummary":595,"conditions":596,"keywords":598,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":600,"lastUpdatePostDateStruct":601,"startDateStruct":602,"completionDateStruct":603,"leadSponsor":605,"locationsCount":40},"100642273","effects-of-different-secukinumab-maintenance-regimens-on-long-term-outcomes-in-patients-with-psoriasis-100642273","NCT07642544","Effects of Different Secukinumab Maintenance Regimens on Long-Term Outcomes in Patients With Psoriasis","Effects of Different Secukinumab Maintenance Regimens on Long-Term Outcomes in Patients With Psoriasis: A Single-Center Real-World Cross-Sectional Retrospective Study","Inclusion Criteria:\n\n* Age ≥ 18 years, with a clinical diagnosis of moderate-to-severe plaque psoriasis.\n* Initiated secukinumab treatment at our center between January 2020 and December 2025, and completed the standard 5-week induction period.\n* Achieved PASI 75 response at the end of the induction period.\n* Had a clearly defined maintenance treatment pattern (standard or non-standard), with complete treatment records and regular efficacy assessments.\n* Complete electronic medical record data available for extraction.\n\nExclusion Criteria:\n\n* Failure to complete the induction period, or failure to achieve PASI 75 response by the end of the induction period.\n* Irregular maintenance treatment pattern, or substantial missing data.\n* Use of other targeted biologic agents or small molecule drugs during the maintenance period.\n* Permanent discontinuation of treatment for non-efficacy reasons, such as pregnancy, severe infection, or malignancy.\n* Participation in other interventional clinical trials that may confound efficacy assessment.",{"count":594,"type":21},120,"To evaluate the long-term efficacy of two maintenance treatment patterns of secukinumab-the standard maintenance group and the non-standard maintenance group-by assessing the median time to onset and incidence of secondary failure, as well as the time to regain response after dose escalation of secukinumab (including re-initiation of intensive dosing or shortening of the injection interval) in patients who experienced secondary failure.",[27,597],"Psoriasis (PsO)",[147,599],"secukinumab","2026-06-09",{"date":546,"type":32},{"date":550,"type":21},{"date":604,"type":21},"2027-03-01",{"name":606,"class":104},"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School",{"id":608,"slug":609,"hasResults":12,"nctId":610,"briefTitle":611,"officialTitle":611,"acronym":612,"eligibilityCriteria":613,"healthyVolunteers":165,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":614,"targetDuration":4,"studyType":22,"phases":615,"briefSummary":616,"conditions":617,"keywords":619,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":623,"lastUpdatePostDateStruct":624,"startDateStruct":625,"completionDateStruct":627,"leadSponsor":629,"locationsCount":556},"100630450","phase-4-the-impact-of-salt-intake-on-sodium-in-the-skin-and-inflammatory-skin-disease-100630450","NCT07487831","The Impact of Salt Intake on Sodium in the Skin and Inflammatory Skin Disease","SIS-ISD","Inclusion Criteria:\n\n* Participants ages 18 years\n* Willing and able to undergo non-contrast MRI.\n\nExclusion Criteria:\n\n* Contraindications to MRI (such as cardiac pacemakers, claustrophobia, non-compatible intracranial vascular clips, IUDs, or other implants)\n* A cardiac event in the past 6 months\n* Impaired function of the liver or kidney (glomerular filtration rate \\\u003C60 mL\u002Fmin)\n* Medications that influence sodium excretion (e.g., diuretics or SGLT2 inhibitors)\n* Antibiotic or immunomodulatory medications within the last month\n* Contraindications to sodium tablets\n\n(Topical medications used exclusively on the head\u002Fneck or hands\u002Ffeet (e.g., antifungal nail treatment, antidandruff shampoo, acne cleansers) are acceptable. Topical and systemic eczema treatments are acceptable if the participant has been on a stable dose for at least 2 months and still meets the severity entry criteria. Patients on dupilumab will not be excluded if they have been on dupilumab for at least two months and still meet the disease severity inclusion criteria.)",{"count":92,"type":21},[214],"The goal of this clinical trial is to demonstrate the feasibility of a trial that examines the impact of changes in dietary sodium intake on skin sodium levels, atopic dermatitis, and psoriasis. In addition, it aims to generate preliminary data to begin to answer the following questions:\n\n1. Is there an association between skin sodium concentration and atopic dermatitis and psoriasis severity?\n2. Are changes in dietary sodium are associated with changes in skin sodium concentration and atopic dermatitis and psoriasis severity?\n\nResearchers will compare sodium tablets to a placebo (a look-alike substance that contains no drug) to specifically examine the impact of altering sodium intake.\n\nParticipants will:\n\n* Follow a low-salt diet for the duration of the 13-week study\n* Take sodium chloride tablets every day for 5 weeks followed by a placebo every day for 5 weeks after a 2-week washout period, or vice versa\n* Visit the clinic up to 4 times to answer questionnaires, provide bio samples, complete dietary recalls, and undergo non-contrast sodium MRI",[618,27],"Atopic Dermatitis (Eczema)",[620,621,622],"sodium","salt","diet","2026-06-05",{"date":600,"type":32},{"date":626,"type":21},"2026-06-22",{"date":628,"type":21},"2028-03-17",{"name":630,"class":104},"University of California, San Francisco"]